All Projects

A

• Abaloparatide-SC for the Treatment of Post-menopausal Osteoporosis

  Abaloparatide-SC is an injectable formulation of abaloparatide developed by Radius Health for the treatment of osteoporosis in post-menopausal women.

  

• Abatacept (Orencia) – Treatment for Rheumatoid Arthritis (RA)

  Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA). It is a biologic drug which contains a selective co-stimulation modulator.

  

• Abecma (idecabtagene vicleucel) for the Treatment of Multiple Myeloma

  Abecma (idecabtagene vicleucel) is the first approved CAR T-cell immunotherapy for relapsed or refractory (r/r) multiple myeloma.

  

• Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia

  Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.

  

• Abraxane for the Treatment of Late-Stage Pancreatic Cancer

  Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.

  

• Abrysvo Vaccine for the Prevention of Respiratory Syncytial Virus, US

  Abrysvo has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

  

• ACE-031 for the Treatment of Duchenne Muscular Dystrophy

  ACE-031 is an investigational protein therapeutic that is being developed by Acceleron Pharma for the treatment of Du

  

• Acomplia (Rimonabant) – Investigational Agent for the Management of Obesity

  Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for

  

• Actemra – Biological Therapy for Rheumatoid Arthritis

  Roche Pharmaceuticals' Actemra (tocilizumab) was approved as a rheumatoid arthritis treatment in the EU in January 2009

  

• Actonel (Risedronate Sodium) – Treatment for Osteoporosis

  Actonel is targeted for the treatment of osteoporosis in postmenopausal women. It is also indicated for the treatment of osteoporosis in men, to improve BMD and Paget's disease.

  

• Adcetris (brentuximab vedotin) for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma

  Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL).

  

• Adempas (Riociguat) for Treatment of Pulmonary Hypertension

  Adempas (riociguat) is indicated for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

  

• Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes

  Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults.

  

• Admelog (insulin lispro) for the Treatment of Type 1 and Type 2 Diabetes

  Admelog® (insulin lispro) is a rapid-acting human insulin analogue approved as a follow-on product to treat type 1 and type 2 diabetes in adults and paediatric patients aged three years and older.

  

• ADUHELM (aducanumab-avwa) for the Treatment of Alzheimer’s Disease

  ADUHELM™ (aducanumab-avwa) is a first-of-its-kind monoclonal antibody indicated for the treatment of Alzheimer’s disease.

  

• ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A

  ADYNOVI® is an intravenous infusion indicated for the treatment of adults and adolescents with haemophilia A.

  

• Afamelanotide, Photo-Protective Drug

  Afamelanotide is a photo-protective drug that increases melanin levels in the human skin to gain protection from ultraviolet radiation (UVR) and sunlight.

  

• Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures

  Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.

  

• Afluria Quadrivalent for Prevention of Infection from Influenza Virus

  Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease.

  

• Afrezza: Mealtime Insulin Therapy for Diabetes

  Afrezza is a rapid-acting insulin therapy indicated for controlling hyperglycaemia in adult patients with type 1 and type 2 diabetes mellitus.

  

• Agamree for the Treatment of Duchenne Muscular Dystrophy, US

  The FDA approved Agamree for the treatment of DMD in October this year.

  

• Aimovig (erenumab) for the Treatment of Episodic Migraine

  Aimovig™ (erenumab) is the first CGRP inhibitor approved for preventive treatment of migraine in adults.

  

• Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)

  Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

  

• Alemtuzumab – Potential in Multiple Sclerosis (MS)

  Alemtuzumab (marketed as Campath/MabCampath/Lemtrada) is an anti-CD52 monoclonal antibody (MAb) for which Bayer HealthCare holds exclusive global marketing rights. It was licensed in 2001 for the treatment of chronic lymphocytic leukaemia.

  

• Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma

  Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

  

• Almorexant for Treatment of Primary Insomnia

  Almorexant is the first member of a new class of drugs called orexin receptor antagonists indicated for the treatment of

  

• Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease

  Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.

  

• Alprolix for the Treatment of Haemophilia B

  Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an intravenous injection indicated for the control and prevention of bleeding episodes, as well as routine prophylaxis in haemophilia B-affected adults and children aged 12 and above.

  

• Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

  Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

  

• AM103 Experimental Treatment for Respiratory Diseases

  Under development by Amira Pharmaceuticals, AM103 is a novel inhibitor of 5-lipoxygenase activating protein (FLAP) that

  

• Amglidia (glibenclamide) for the Treatment of Neonatal Diabetes

  Amglidia is a hybrid medicine indicated for the treatment of neonatal diabetes mellitus in newborns, infants, and children.

  

• Amondys 45 (Casimersen) for the Treatment of Duchenne Muscular Dystrophy

  Amondys 45 (casimersen) injection is an antisense oligonucleotide indicated for the treatment of patients with Duchenne muscular dystrophy (DMD). It is the first US Food and Drug Administration (FDA)-approved treatment for patients with DMD with a mutation amenable to skipping exon 45.

  

• AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia

  Under development by Amarin Corporation, AMR101 is a partially synthetic omega-3 fatty acid-based drug. It contains the

  

• AMVUTTRA (vutrisiran) for the Treatment of Polyneuropathy of hATTR Amyloidosis, USA

  AMVUTTRA™ (vutrisiran) is the first FDA-approved drug to reverse neuropathy impairment in hATTR amyloidosis patients.

  

• AN2728 for the Treatment of Psoriasis

  AN2728 is an anti-inflammatory drug being developed by Anacor Pharmaceuticals as a treatment for psoriasis.

  

• Anacetrapib – Treatment for Atherosclerosis

  Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of atherosclerosis.

  

• Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) for the Treatment of Factor Xa Inhibitor-Associated Acute Major Bleeding

  Andexxa® (coagulation factor Xa recombinant, inactivated-zhzo) is an intravenous infusion indicated for the treatment of patients with factor Xa inhibitor-associated acute major bleeding.

  

• ANKTIVA for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC), USA

  ANKTIVA® is a next-generation immunotherapy to treat BCG-unresponsive non-muscle invasive bladder cancer.

  

• Anoro Ellipta for Treatment of Chronic Obstructive Pulmonary Disease

  Anoro ellipta (umeclidinium bromide / vilanterol) is a dry powder for inhalation, indicated for the treatment of airflow obstructions in patients suffering from chronic obstructive pulmonary disease (COPD) or emphysema.

  

• Anthim (obiltoxaximab) Injection for the Treatment of Inhalational Anthrax

  Anthim (obiltoxaximab) is an injectable drug developed by Elusys Therapeutics for the treatment of inhalational anthrax caused by bacillus anthracis.

  

• APD125 – Therapy for Insomnia

  Developed by Arena Pharmaceuticals, APD125 is an oral serotonin antagonist with potential for the treatment of insomnia.

  

• Aphexda (Motixafortide) for Stem Cell Mobilisation for Autologous Transplantation for Multiple Myeloma, USA

  Aphexda™ is a first-of-its-kind product approved for stem cell mobilisation for multiple myeloma in approximately ten years.

  

• Apretude (cabotegravir) for the Treatment of HIV-1 Pre-Exposure Prevention (PrEP)

  Apretude (cabotegravir) is indicated for the treatment of HIV-1 PrEP to minimise the risk of HIV-1 infection.

  

• Aptiom® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures

  Aptiom (eslicarbazepine acetate) is a sodium channel inhibitor approved as an adjunctive treatment for partial-onset seizures in the US and Europe.

  

• Arexvy (RSV vaccine) to Prevent Lower Respiratory Tract Disease (LRTD), USA

  Arexvy is the world’s first respiratory syncytial virus vaccine to prevent lower respiratory tract disease in older adults.

  

• Ariflo (Cilomilast) – Oral PDE-IV Inhibitor for

  Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor under development by GlaxoSmithKline Pharm

  

• Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia

  Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults.

  

• Artesunate for Injection for the Treatment of Severe Malaria

  Artesunate for Injection is an antimalarial drug indicated for the initial treatment of severe malaria in adult and paediatric patients. It is the only drug in the US to treat the condition.

  

• Arzerra (Ofatumumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)

  Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL).

  

• ASA404 Vascular Disrupting Agent for Solid Tumours

  ASA404 is a vascular disrupting agent (VDA) that was being developed by Antisoma and Novartis as a treatment for a range

  

• ASP-1929 for the Treatment of Head and Neck Squamous Cell Carcinomas

  ASP-1929 is a first-in-class therapy indicated for the treatment of head and neck squamous cell carcinomas (HNSCC).

  

• AstraZeneca’s Brilinta – Treatment for Acute Coronary Syndrome

  Brilinta is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots. It was developed by AstraZeneca for the treatment of acute coronary syndrome (ACS).

  

• Atogepant for the Preventive Treatment of Migraine, US

  Atogepant binds to the CGRP receptor on the brain’s trigeminal nerve and blocks the activation of the migraine.

  

• Aubagio (Teriflunomide) for the Treatment of Multiple Sclerosis

  Aubagio (teriflunomide) is an immunomodulatory agent indicated for the treatment of relapsing forms of multiple sclerosis (MS). It was developed by Genzyme.

  

• Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

  Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

  

• Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder (MDD), USA

  Auvelity™ (dextromethorphan and bupropion) is the first and only oral rapid-acting antidepressant for major depressive disorder.

  

• Avastin (bevacizumab) – Angiogenesis Inhibitor and Cancer Therapy

  The product of a joint development programme between Genentech and Roche, Avastin (bevacizumab) is a humanised monoclonal antibody (MAb) directed against vascular endothelial growth factor (VEGF), a pro-angiogenesis factor.

  

• Aveed (testosterone undecanoate) for the Treatment of Men with Hypogonadism

  Aveed (testosterone undecanoate) is a testosterone replacement therapy indicated for the treatment of hypogonadism in adult men who are associated with a deficiency or absence of the male hormone testosterone.

  

• Axitinib – Treatment for Advanced Renal Cell Carcinoma

  Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.

  

• AYVAKIT (avapritinib) for the Treatment of Gastrointestinal Stromal Tumours (GISTs)

  AYVAKIT™ (avapritinib) is the first precision therapy approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumours (GISTs) and advanced systemic mastocytosis (ASM).

  

B

• BALVERSA for the Treatment of Urothelial Carcinoma, US

  BALVERSA is available as a round, biconvex, film-coated tablet in 3mg, 4mg, or 5mg strengths.

  

• Bamlanivimab (LY-Cov555) for the Treatment of Covid-19

  Bamlanivimab (LY-CoV555) is a neutralising monoclonal antibody intended for the treatment of mild to moderate COVID-19.

  

• Banzel – Treatment for Lennox-Gastaut syndrome

  Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures.

  

• Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma

  Bavencio® (avelumab) is a human PD-L1 monoclonal antibody indicated for the treatment of metastatic Merkel-cell carcinoma (MCC).

  

• Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

  Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

  

• Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)

  Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

  

• Belsomra (suvorexant) for the Treatment of Insomnia

  Belsomra (suvorexant) is the only approved drug of its kind for treating adult patients suffering from insomnia characterised by difficulty with sleep onset or sleep maintenance. The drug was developed by Merck, Sharp & Dohme Corp.

  

• Benlysta – Lupus Treatment

  Benlysta is an investigational human monoclonal antibody drug indicated for treating autoantibody-positive systemic lupu

  

• Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)

  Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

  

• BESPONSA (inotuzumab ozogamicin) for the Treatment of Acute Lymphoblastic Leukaemia

  BESPONSA® is an intravenous infusion indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

  

• BESREMi (ropeginterferon alfa-2B) for the Treatment of Polycythaemia Vera, US

  BESREMi® (ropeginterferon alfa-2B) is a mono-pegylated proline interferon indicated for the treatment of polycythaemia vera.

  

• Bevyxxa (betrixaban) for the Treatment of Venous Thromboembolism (VTE) in Adults

  Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.

  

• Bexsero – Treatment for Meningitis B (MenB) Disease

  Discovered and developed by Novartis, Bexsero is a vaccine indicated for the treatment of meningococcal group B (MenB) disease. It is the first and the only Men B vaccine for the protection of all age groups against the disease.

  

• Bifeprunox – Atypical Antipsychotic Drug

  Bifeprunox mesilate was a novel atypical antipsychotic agent under development by Solvay Pharmaceuticals as a treatment

  

• Biktarvy for the Treatment of HIV-I

  Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.

  

• Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia

  Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.

  

• BNC105

  BNC105, being developed by Adelaide-based Bionomics, is a new kind of drug known as a vascular targeting agent (VDA). As

  

• Boceprevir, Experimental Drug for Chronic Hepatitis C Infection by Schering-Plough

  Victrelis (boceprevir) is an oral HCV protease inhibitor indicated for the treatment of chronic infection with hepatitis

  

• Boostrix – Vaccine for Whooping Cough, Tetanus and Diphtheria

  Boostrix is a three-in-one vaccine administered to protect against whooping cough, tetanus and diphtheria. Vaccination is an effective way to protect against them.

  

• Bosutinib – Chronic Myelogenous Leukaemia (CML) Treatment

  Bosutinib is an investigational drug indicated for treating Philadelphia chromosome positive Chronic Myelogenous Leuka

  

• Breo Ellipta for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

  Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

  

• Brexafemme (ibrexafungerp) for the Treatment of Vaginal Yeast Infection

  Brexafemme (ibrexafungerp) is the first FDA-approved oral non-azole treatment for vaginal yeast infections.

  

• Breyanzi for the Treatment of Large B-cell Lymphoma, US

  Breyanzi is a gene-modified autologous therapy.

  

• Brintellix (Vortioxetine) for Treatment of Major Depressive Disorder (MDD)

  Brintellix (vortioxetine) is a new multimodal antidepressant indicated for the treatment major depressive disorder (MDD) in adults.

  

• Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, USA

  Briumvi™ is the first and only approved anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis.

  

• Briviact (brivaracetam) For the Treatment of Partial Onset Seizures

  Briviact (brivaracetam) was developed by UCB for the treatment of partial onset of seizures in epilepsy patients over the age of 16.

  

• Brukinsa (zanubrutinib) for the Treatment of Waldenstrom’s Macroglobulinaemia, USA

  Brukinsa® (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene.

  

• Bydureon® BCise™ for the Treatment of Type-2 Diabetes

  Bydureon® BCise™ (exenatide extended-release) is an injectable suspension containing a glucagon-like peptide-1 (GLP-1) receptor agonist. 

  

• Byetta (exenatide) – First-in-Class Incretin Mimetic for Type 2 Diabetes

  Developed by Amylin Pharmaceuticals, Byetta (exenatide) is a synthetic exendin-4 agent indicated for the treatment of ty

• Bylvay (odevixibat) for the Treatment of Pruritus, USA

  Bylvay™ is indicated to treat skin itching caused by certain inherited liver conditions, PFIC and Alagille syndrome.

  

C

• Cabenuva (cabotegravir and rilpivirine) for the Treatment of HIV-1 Infection, USA

  Cabenuva is the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults.

  

• Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

  Cablivi™ (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP).

  

• Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma

  Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).

  

• Calquence (acalabrutinib) for the Treatment of Mantle Cell Lymphoma

  Calquence® (acalabrutinib) is a bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL).

  

• Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

  Camzyos® (mavacamten) is the only FDA-approved cardiac myosin inhibitor that particularly targets the source of obstructive HCM.

  

• Capravirine – Anti-Retroviral Drug

  Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NN

  

• Caprospinol, Therapy for Alzheimer’s Disease (AD)

  Samaritan Pharmaceuticals' caprospinol (SP-233) is an investigational
  agent under development for the treatment of Alzh

  

• Carnexiv (carbamazepine) for the Treatment of Certain Seizure Types in Adults

  Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication.

  

• Carvykti (ciltacabtagene autoleucel) for the Treatment of Multiple Myeloma

  Carvykti™ (ciltacabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM).

  

• Ceftazidime-Avibactam for Treatment of Complicated Urinary Tract and Intra-Abdominal Infections

  Ceftazidime-avibactam is an investigational antibiotic indicated for treatment of patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Actavis is jointly developing the drug in collaboration with AstraZeneca.

  

• Ceftobiprole – Injectable Anti-MRSA Cephalosporin Antibiotic

  The product of a joint development programme between the Swiss pharmaceutical company Basilea Pharmaceutica AG and Cilag AG International (a Johnson & Johnson company), ceftobiprole medocaril (BAL5788) is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.

  

• Celvapan – H1N1 Pandemic Influenza Vaccine

  The Celvapan pandemic vaccine is being developed by Baxter International. It was first developed as a mock-up vaccine co

  

• Cepheid Xpert vanA Test Kit

  Xpert vanA is a new diagnostic test kit developed by California-based Cepheid for the early and easy detection of vancom

  

• Cerovive – Neuroprotectant for the

  Cerovive, a nitrone-based free radical scavenger indicated for the treatment of acute ischaemic stroke has been disconti

  

• Cervarix, Cervical Cancer Vaccine by GlaxoSmithKline

  GlaxoSmithKline's (GSK) Cervarix is a prophylactic vaccine currently indicated for the prevention of precancerous cervic

  

• Cetilistat – Investigational Drug for Obesity

  Developed by Alizyme, a specialist biopharmaceutical company in collaboration with Takeda Pharmaceutical, cetilistat (AT

  

• Chronic Plaque Psoriais Treatment with ILUMYA

  ILUMYA™ (tildrakizumab-asmn) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

  

• CIBINQO (abrocitinib) to Treat Moderate to Severe Atopic Dermatitis

  CIBINQO (abrocitinib) is a once-daily, oral, prescription medicine to treat moderate to severe atopic dermatitis.

  

• Cilansetron – New Treatment for IBS

  Developed by Solvay Pharmaceuticals, cilansetron is a 5-HT3 antagonist indicated for the treatment of diarrhoea-predomin

  

• CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

  CIMZIA® (certolizumab pegol) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

  

• Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype

  Cinqair is an injectable formulation of reslizumab developed by Teva Pharmaceuticals for the treatment of severe asthma and eosinophilic phenotype in adults.

  

• COBENFY for the Treatment of Schizophrenia, US

  Schizophrenia is a chronic and debilitating mental disorder that impacts the way an individual thinks, feels, and acts.

  

• Columvi (Glofitamab-gxbm) for the Treatment of Diffuse Large B-Cell Lymphoma, USA

  Columvi is a bispecific antibody, fixed-duration treatment for relapsed or refractory diffuse large B-cell lymphoma.

  

• Contrave for the Treatment of Obesity

  Contrave (Bupropion / naltrexone) is a drug indicated for treating obesity. The drug was developed by Orexigen Therapeutics.

  

• COPIKTRA (duvelisib) Indicated for chronic lymphocytic leukaemia

  COPIKTRA (duvelisib) is a dual phosphoinositide 3-kinase (PI3K) inhibitor indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) or follicular lymphoma (FL).

  

• Corifact – Treatment for Rare Form of Haemophilia

  Corifact is an intravenous drug indicated for the treatment of bleeding disorder in patients with factor XIII deficien

• Corlanor (Ivabradine) for the Treatment of Heart Failure

  Corlanor (ivabradine) is an oral medication approved to reduce the risk of hospitalisation for worsening heart failure in patients facing chronic heart failure risk due to the lower-left part of the heart not contracting well.

  

• COSELA™ (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression, US

  COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced bone marrow suppression in adult patients.

  

• Cosentyx (secukinumab) for Treatment of Plaque Psoriasis

  Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A).

  

• COVAXIN (BBV152) for the Treatment of Covid-19, India

  COVAXIN™ (BBV152) is the first Covid-19 vaccine developed completely in India.

  

• Cresemba® (isavuconazonium sulphate) for the Treatment of Invasive Aspergillosis and Mucormycosis

  Cresemba (isavuconazonium sulphate) is an antifungal drug indicated for the treatment of invasive aspergillosis and invasive mucormycosis, which is also known as zygomycosis.

  

• Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

  Crysvita® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adults and children.

  

• Cuvposa – Treatment for Chronic Drooling

  Cuvposa (Glycopyrrolate) is the first and only approved drug for controlling drooling in patients aged between three

  

• CXL-1020 Treatment for Patients with Acute Decompensated Heart Failure (ADHF)

  CXL-1020 is an investigational therapeutic agent being developed for treating patients with acute decompensated heart fa

  

• Cymbalta (Duloxetine HCl) for Chronic Musculoskeletal Pain Management

  Cymbalta (Duloxetine hydrochloride) is indicated for treating chronic musculoskeletal pain as a result of osteoarthritis

  

• Cyramza (ramucirumab) for the Treatment of Gastric Cancer

  Cyramza (ramucirumab) is a human monoclonal antibody for the treatment of Gastric cancer.

  

• Cystaran (cysteamine hydrochloride) for Treatment of Cystinosis

  Cystaran (cysteamine hydrochloride) is a cystine-depleting agent indicated for the treatment of cystinosis.

  

• Cytalux (pafolacianine) for Identification of Ovarian Cancer

  Cytalux is the first intraoperative fluorescent imaging drug that helps in identifying ovarian cancer lesions during surgery.

  

D

• Daklinza (daclatasvir) for the Treatment of Chronic Hepatitis C Genotype 3 Infection

  Daklinza (daclatasvir), an NS5A replication complex inhibitor, is the first 12-week, all-oral therapy indicated for use with sofosbuvir, for the treatment of hepatitis C (HCV) genotype 3 infections.

  

• Daliresp (Roflumilast), Treatment to Reduce COPD

  Daliresp (Roflumilast) is an oral tablet that is proved to reduce the risk of exacerbations in patients suffering from

  

• Dalvabancin – Second-Generation Glycopeptide for Serious Gram-Positive Infections

  Originally developed by Vicuron Pharmaceuticals (which was subsequently acquired by Pfizer and then Durata Therapeutics)

  

• DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma

  DANYELZA® (naxitamab-gqgk) is a humanised immunotherapy indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of high-risk neuroblastoma (HR-NB).

  

• Darapladib – Selective Lp-PLA2 Inhibitor for Prevention of Atherosclerosis

  Darapladib is a selective LpPLA2 inhibitor under development by GlaxoSmithKline (GSK). The drug is targeted at coronary

  

• Darzalex (daratumumab) for the Treatment of Multiple Myeloma

  Darzalex (daratumumab) is the world's first human anti-CD38 monoclonal antibody (mAb) approved for the treatment of patients with multiple myeloma.

  

• DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the Treatment of Light Chain (AL) Amyloidosis

  DARZALEX FASPRO^® (daratumumab and hyaluronidase-fihj) is the first subcutaneous therapy approved for the treatment of newly diagnosed light chain (AL) amyloidosis in adult patients.

  

• Dasatinib – Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)

  Dasatinib is a new, oral small-molecule tyrosine kinase inhibitor (TKI) developed by Bristol Myers Squibb for the trea

  

• Defitelio (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease

  Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

  

• Delstrigo for the Treatment of HIV-1 Infection

  Delstrigo™ is a fixed-dose combination tablet of antiretroviral drugs doravirine, lamivudine, and tenofovir disoproxil fumarate indicated for the treatment of human immunodeficiency virus (HIV) 1 infection.

  

• Descovy (emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection

  Descovy (emtricitabine200mg/tenofovir alafenamide25mg, F/TAF) is developed by Gilead sciences for the treatment of HIV-1 infection in adults and children above 12 years of age.

  

• Dificid (fidaxomicin) – Narrow-Spectrum Antibiotic for Clostridium Difficile Infection

  Dificid (fidaxomicin) is the first in a new class of antibiotics developed by Optimer Pharmaceuticals to treat Clostridi

  

• Dimebon – Investigational Compound Indicated for the Treatment of Alzheimer’s and Huntington’s Disease

  Dimebon (latrepirdine) is an investigational compound indicated for the treatment of Alzheimer's and Huntington's diseas

  

• Dinutuximab beta for the Treatment of Neuroblastoma

  Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

  

• Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia

  Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).

  

• Doripenem – A New Broad-Spectrum Carabapenem Antibiotic

  Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Ph

  

• Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection

  Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults.

  

• Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

  Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD).

  

• Dulera (Mometasone Furoate and Formoterol Fumarate Dihydrate) – Treatment for Asthma

  Dulera (mometasone furoate and formoterol fumarate dihydrate) is a new fixed-dose combination inhaler for the treatment of asthma.

  

• Dupixent (dupilumab) for the Treatment of Atopic Dermatitis, US

  Dupixent (dupilumab) is the first targeted treatment for children as young as six months old with severe atopic dermatitis.

  

• Durlaza (aspirin) for Reducing Risk of Cardiovascular Events

  Durlaza (aspirin) is a non steroidal anti-inflammatory drug indicated for the prevention of thrombotic events in patients with cardiovascular disease (CVD).

  

• Duvyzat (givinostat) for the Treatment of Duchenne Muscular Dystrophy (DMD), USA

  Duvyzat™ (givinostat) is the first non-steroidal drug approved to treat all genetic variants of Duchenne muscular dystrophy (DMD).

  

• Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout

  Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI).

  

• Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients

  Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older.

  

E

• Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection

  Ebanga (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody for the treatment of Zaire ebolavirus infection in adult and paediatric patients.

  

• Edarbi for the Treatment of Hypertension

  Edarbi (Azilsartan medoxomil) was developed by Takeda Pharmaceuticals for the treatment of hypertension in adults.

  

• Edoxaban, Oral Anticoagulant

  Lixiana (edoxaban) is an oral anticoagulant developed by Daiichi Sankyo, a pharmaceutical company based in Japan. It is

  

• Edurant (rilpivirine) for the Treatment of HIV-1 Infection

  Edurant (rilpivirine) is an antiviral drug indicated for treatment-naive adults with HIV-1 infection.

  

• Elacytarabine (CP-4055) for Treatment of Acute Myeloid Leukaemia

  Elacytarabine (CP-4055) is a lipid-conjugated version of cytarabine, an anti-cancer agent drug approved for the treatmen

  

• ELAHERE for the Treatment of Ovarian Cancer, US

  AbbVie acquired ImmunoGen in February 2024, which added ELAHERE to its portfolio.

  

• Elelyso (Taliglucerase Alfa) for Treating Gaucher Disease

  Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and Pfizer.

  

• ELEVIDYS (delandistrogene moxeparvovec) for the Treatment of Duchenne Muscular Dystrophy, USA

  Elevidys (delandistrogene moxeparvovec) is the first gene therapy approved to treat Duchenne muscular dystrophy in children.
  

  

• Eliquis (apixaban) for Prevention of Stroke in Nonvalvular Atrial Fibrillation (NVAF) Patients

  Eliquis (apixaban) is an anticoagulant drug that was jointly developed by Bristol-Myers Squibb and Pfizer.

  

• Eloctate™ for the Treatment of Haemophilia A

  Eloctate is a drug approved for the control and prevention of bleeding episodes in children and adult haemophilia A patients.

  

• Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma

  Elotuzumab (HuLuc63) is an anti-CS1 humanised monoclonal antibody (MAb) developed by PDL Biopharma. In December 2008 PDL

  

• ELREXFIO (elranatamab) for the Treatment of Multiple Myeloma, USA

  ELREFXIO™ (elranatamab) is a targeted immunotherapy to treat adult patients with relapsed and refractory multiple myeloma (RRMM).

  

• Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN

  Elzonris™ (tagraxofusp-erzs) is an interleukin-3 receptor alpha chain (CD123) directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and paediatric patients.

  

• Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy

  Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD).

  

• EMPAVELI (pegcetacoplan) for the Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)

  EMPAVELI™ (pegcetacoplan) is the first and only targeted complement component 3 (C3) therapy indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.

  

• Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

  Empliciti (elotuzumab) is an immunostimulatory antibody indicated for the treatment of multiple myeloma.

  

• Enbrel – Immunosuppressant for Treatment of Rheumatoid Arthritis

  Enbrel is an immunosuppressant that inhibits the production of tumour necrosis factor (TNF) in patients suffering from r

  

• Endari for the Treatment of Sickle Cell Disease

  Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.

  

• ENHERTU (fam-trastuzumab deruxtecan-nxki) for the Treatment of HER2 Positive Advanced Gastric Cancer

  Enhertu is a HER2-directed antibody-drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo.

  

• Enjaymo (sutimlimab-jome) for the Treatment of Cold Agglutinin Disease (CAD)

  Enjaymo™ (sutimlimab-jome) is a classical complement inhibitor that works by inhibiting the haemolysis of red blood cells.

  

• Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

  Enspryng™ (satralizumab-mwge) is the first and only US Food and Drug Administration (FDA)-approved subcutaneous therapy indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adult patients.

  

• Entecavir (Baraclude) – Oral Antiviral Drug for Hepatitis-B Infection

  Discovered by Bristol-Myers Squibb (BMS), Entecavir / Baraclude is an antiviral drug for treating chronic Hepatitis B.

  

• Entresto (Sacubitril / Valsartan) for the Treatment of Heart Failure

  Entresto (sacubitril/valsartan) is an angiotensin II receptor blocker indicated for the treatment of chronic heart failure.

  

• Entyvio for the Treatment of Ulcerative Colitis and Crohn’s Disease, US

  Positive clinical trail results for Entyvio have led to its approval in both the US and EU markets.

  

• Epanova for the Treatment of Hypertriglyceridemia

  Epanova (omega-3-carboxylic acids) is indicated for the treatment of adult patients with severe hypertriglyceridaemia.

  

• Epclusa (Sofosbuvir/ Velpatasvir) for the Treatment of Hepatitis C

  Epclusa (Sofosbuvir/ Velpatasvir) is an oral formulation developed by Gilead Sciences for the treatment of 1-6 chronic hepatitis C virus (HCV) infection.

  

• EPIDIOLEX (cannabidiol) for Seizures Associated with Lennox-Gastaut and Dravet Syndromes

  EPIDIOLEX® is a cannabidiol (CBD) based drug indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).

  

• Epkinly (epcoritamab-bysp) for the Treatment of Diffuse Large B-Cell Lymphoma, USA

  Epkinly™ (epcoritamab-bysp) is the first bispecific antibody to treat adults with diffuse large B-cell lymphoma.

  

• Erbitux (Cetuximab)

  Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for the epidermal growth factor receptor (EGFR). A new

  

• Erivedge (vismodegib) – Treatment for Advanced Basal Cell Carcinoma

  Erivedge (vismodegib) is a Hedgehog pathway inhibitor indicated for the treatment of advanced basal cell carcinoma (BCC) in adults.

  

• Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

  Erleada™ (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).

  

• Erwinaze (Asparaginase Erwinia Chrysanthemi) – Treatment for ALL

  Erwinaze (asparaginase Erwinia chrysanthemi) is indicated for the treatment of acute lymphoblastic leukaemia (ALL). It is manufactured by EUSA Pharma.

  

• Eskata (hydrogen peroxide) for the Treatment of Raised Seborrheic Keratoses (SK), USA

  Eskata® (hydrogen peroxide) is a topical, non-invasive treatment for raised seborrheic keratoses (SK) in adults.

  

• Esperoct (turoctocog alfa pegol) for the Treatment of Haemophilia A

  Esperoct® (turoctocog alfa pegol) is a recombinant factor indicated for the treatment of haemophilia A in adults and children.

  

• ETC-216 – Phospholipid

  Developed by US biopharmaceutical company Esperion Therapeutics, ETC-216 is a synthetic variant of high-density lipoprot

  

• Eviplera – Treatment for HIV

  Eviplera is a single-pill regimen targeted at human immunodeficiency virus-1 (HIV-1). It combines the active substances emtricitabine, rilpivirine and tenofovir disoproxil.

  

• Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection

  Evotaz (atazanavir and cobicistat) is a protease inhibitor indicated for the treatment of HIV-1 infection in adults.

  

• Evrysdi for the Treatment of Spinal Muscular Atrophy, US

  Evrysdi is the first and only oral medication indicated for the treatment of SMA in patients.

  

• Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19

  Evusheld is a long-acting antibody combination therapy for the pre-exposure prevention of Covid-19 in high-risk patients.

  

• Exanta – Oral Direct Thrombin Inhibitor for the

  Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI) under development by AstraZeneca. As the first fixed-do

  

• Exjade (Deferasirox) for Treating Chronic Iron Overload, US

  Exjade (deferasirox) is an oral iron chelator developed and manufactured by Novartis. It is indicated for the treatment of iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes.

  

• Exkivity (mobocertinib) for the Treatment of Non-Small Cell Lung Cancer

  Exkivity is the first and only oral therapy indicated for non-small cell lung cancer with EGFR exon 20 insertion mutations.

  

• Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)

  Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics.

  

• Exparel for Postsurgical Pain Relief

  Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical pain.

  

• Exubera – Inhaled Insulin

  The product of a joint development programme between Aventis and Pfizer, Exubera is an inhaled short-acting insulin prep

• Eylea (Aflibercept) for Treatment for Wet AMD

  Eylea (aflibercept), a recombinant fusion protein, was developed for the treatment of patients with wet age-related macular degeneration (AMD).

  

F

• Fabhalta (iptacopan) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria, USA

  Fabhalta (iptacopan) is the first oral monotherapy indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

  

• Fablyn (Lasofoxifene) – Investigational SERM

  The product of a joint development programme between Pfizer and Ligand Pharmaceuticals, Fablyn, formerly Oporia (lasofoxifene) is a selective oestrogen receptor modulator (SERM).

• Fampridine-SR – Treatment for Multiple Sclerosis

  Developed by Acorda Therapeutics and manufactured by Elan Corporation, fampridine-SR (now referred to as AMPYRA) is a se

  

• Farydak® (panobinostat) for the Treatment of Multiple Myeloma

  Farydak (panobinostat, previously known as LBH589) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with multiple myeloma.

  

• Fasenra (benralizumab) for the Treatment of Asthma

  Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

  

• Faslodex (fulvestrant) for the Treatment of Advanced Breast Cancer

  Faslodex (fulvestrant) is an oestrogen receptor antagonist indicated for the treatment of locally advanced or metastatic breast cancer.

  

• FETROJA (cefiderocol) for the Treatment of Bacterial Pneumonia

  FETROJA® (cefiderocol) is the first approved siderophore cephalosporin antibacterial drug.

  

• Fetzima (Levomilnacipran) – Treatment for Major Depressive Disorder (MDD)

  Fetzima (levomilnacipran) is an antidepressant indicated for treatment of adult patients suffering from major depressive disorder (MDD).

  

• Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes

  Discovered and developed by Novo Nordisk, Fiasp® (insulin aspart) is a fast-acting insulin analogue indicated for the treatment of adults with Type 1 and Type 2 diabetes.

  

• Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, USA

  Filspari (sparsentan) is the first approved non-immunosuppressive therapy for reducing proteinuria in IgA nephropathy.

  

• Fingolimod – Novel Therapy for Multiple Sclerosis

  Fingolimod (branded Gilenya) is an innovative treatment for multiple sclerosis (MS) under development by Novartis. The d

  

• FINTEPLA (Fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome, USA

  FINTEPLA® (fenfluramine) is indicated to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.
  

  

• FIRAZYR – Treatment for Hereditary Angioedema

  FIRAZYR (Icatibant) is a drug developed and manufactured by Jerini, which was taken over by Shire Pharmaceuticals in 2008. The drug is indicated for the treatment of Hereditary Angioedema (HAE).

  

• Firdapse (amifampridine) for Lambert-Eaton Myasthaenic Syndrome

  Firdapse® (amifampridine) is one of the first drugs to be approved for the treatment of Lambert-Eaton myasthaenic syndrome (LEMS) in adults.

  

• Florbetaben

  Alzheimer's disease (AD) is the most common type of dementia, which severely impacts the intellectual abilities of a

  

• Flucelvax Vaccine for Protection Against Seasonal Influenza

  Flucelvax, developed by Novartis in association with the US Department of Health and Human Services, is a vaccine that provides protection against seasonal influenza for adult patients aged 18 years and above.

  

• Fludase – Experimental Antiviral Drug for Influenza

  NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181).

  

• FluLaval Influenza Virus Vaccine

  FluLaval is an influenza vaccine that was approved by the US FDA on 23 July 2010, for use on people who are 18 years and

  

• Flurizan – Anti-Amyloid Drug for Treatment of Alzheimer’s Disease

  Myriad Pharmaceuticals' Flurizan (tarenflurbil) is a selective amyloid lowering agent under development for the treatmen

  

• Flutiform (fluticasone proprionate and formoterol fumarate) for Treatment of Asthma

  Flutiform (fluticasone proprionate and formoterol fumarate) is a combination therapy used for the treatment of asthma.

  

• Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes

  Forxiga® (dapagliflozin) is approved for the treatment of paediatric type 2 diabetes, chronic heart failure and chronic kidney disease.

  

• FOTIVDA (tivozanib) for the Treatment of Renal Cell Carcinoma

  FOTIVDA® (tivozanib) is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) in adult patients.

  

• FRUZAQLA (fruquintinib) for the Treatment of Metastatic Colorectal Cancer, USA

  FRUZAQLA® (fruquintinib) is an oral targeted therapy indicated for adult patients with metastatic colorectal cancer (mCRC).

  

• Fulyzaq (Crofelemer) for the Treatment of HIV / AIDS-Associated Diarrhoea

  Fulyzaq (crofelemer) is an anti-infective drug which is derived from a botanical source. It is indicated for the treatment of non-infectious diarrhoea in HIV / AIDS patients who are on anti-retroviral therapy (ART).

  

• Fycompa (perampanel) – Treatment for Epilepsy

  Fycompa (perampanel / E2007) is an AMPA-type glutamate receptor antagonist indicated for the treatment of epilepsy. It was developed by Japan-based healthcare company Eisai.

  

G

• Gaboxadol – Investigational Agent

  Gaboxadol is a direct-acting gamma-amino butyric acid (GABA)A agonist under development by Danish pharmaceutical company

  

• Galafold (migalastat) Indicated for the Treatment of Fabry Disease

  Galafold™ (migalastat) is indicated for the treatment of adult patients aged 16 years and older with Fabry disease.

  

• Galida – Dual PPAR

  AstraZeneca's, Galida (tesaglitazar) is a dual-acting oral Peroxisome Proliferator-Activated Receptor (PPAR) agonist tha

  

• Gamifant (emapalumab-lzsg) for Primary Haemophagocytic Lymphohistiocytosis

  Gamifant® (emapalumab-lzsg) is an interferon-gamma (IFNγ) blocking antibody indicated for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in paediatric and adult patients.

  

• Gardasil 9 Vaccine for Prevention of Cancers Caused by Human Papillomavirus (HPV)

  Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) is indicated for the prevention of cancers caused by some types of human papillomavirus (HPV).

  

• Gattex (Teduglutide) for Treatment of Short Bowel Syndrome (SBS)

  Gattex (teduglutide) is a subcutaneous injection indicated for the treatment of adult patients with short bowel syndrome (SBS). The drug was developed and manufactured by NPS Pharmaceuticals in association with Takeda Pharmaceuticals.

  

• Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

  Gavreto™ (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), diagnosed by a US Food and Drug Administration (FDA)-approved test, in adult patients.

  

• Gazyva (obinutuzumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)

  Gazyva (obinutuzumab / GA101) is a monoclonal antibody indicated for the treatment of chronic lymphocytic leukaemia (CLL).

  

• GEMTESA for the Treatment of Overactive Bladder, US

  GEMTESA’s long-term safety, tolerability, and efficacy in adults with OAB was evaluated in a 40-week Phase III EMPOWUR extension study.

  

• Gilotrif (afatinib) for the Treatment of Metastatic Non-Small cell Lung Cancer

  Gilotrif (afatinib) is an orally administered drug that is indicated as the first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.

  

• Givlaari™ (givosiran) for the Treatment of Acute Hepatic Porphyria

  Givlaari™ (givosiran) is the first aminolevulinic acid synthase 1 (ALAS1)-targeting RNAi drug indicated for the treatment of acute hepatic porphyria (AHP) in adults.

  

• Glatopa (glatiramer acetate injection) for the Treatment of Multiple Sclerosis

  Glatopa (glatiramer acetate injection, formerly M356) is the first substitutable generic drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS).

  

• GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus

  GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus.

  

• Glybera (alipogene tiparvovec) for Treatment of Lipoprotein Lipase Deficiency (LPLD)

  Glybera (alipogene tiparvovec) is a gene therapy indicated for the treatment Lipoprotein Lipase Deficiency (LPLD). It was developed by Amsterdam Molecular Therapeutics (AMT), which was acquired by uniQure in April 2012.

  

• GRNOPC1 for spinal-cord injury

  GRNOPC1 is an indicative stem cell therapy developed by Geron for the treatment of spinal cord injuries (SCI).

  

H

• Haegarda for the Preventive Treatment of Hereditary Angioedema

  Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

  

• Haiyitan for the Treatment of Non-Small Cell Lung Cancer, Japan

  The NMPA granted conditional approval for Haiyitan in China for NSCLC patients with METex14 skipping mutations in 2023.

  

• Halaven – Treatment of Metastatic Breast Cancer

  Halaven is a non-taxane drug developed by Eisai Co. for the treatment of metastatic breast cancer.

  

• Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma

  Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy.

  

• Harvoni (ledipasvir/sofosbuvir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection

  Developed by Gilead Sciences, Harvoni (ledipasvir/sofosbuvir) is the first combination pill approved for the treatment of adult patients with chronic hepatitis C genotype 1 infection.

  

• Hemlibra® (emicizumab-kxwh) for the Treatment of Haemophilia A with Inhibitors

  Hemlibra® (emicizumab-kxwh) is an antibody indicated to reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

  

• Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers

  Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

  

• Hetlioz (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder

  Hetlioz (tasimelteon) is the first and only drug approved in the European Union (EU) for non-24-hour sleep-wake disorder (Non-24).

  

• Hizentra for the Treatment of Patients with CIDP

  Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

  

• Horizant – Treatment for Restless Legs Syndrome

  Horizant is a non-dopaminergic therapy indicated for the treatment of restless legs syndrome (RLS). It was developed by XenoPort and is marketed by GSK in the US.

  

• HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis

  HUMIRA is the only subcutaneous therapy approved by the US Food and Drug Administration (FDA) for the treatment of ulcerative colitis in paediatric patients aged five years and above.

  

• Humira for the Treatment of Hidradenitis Suppurativa

  Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.

  

• Hycamtin – Anti-Tumour Drug for Treatment of Relapsed Small Cell Lung Cancer

  Hycamtin is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for relapsed small cell lung cancer (S

  

• Hydroxychloroquine for Potential Covid-19 Treatment

  Hydroxychloroquine, marketed by Sanofi under the trade name Plaquenil, is primarily indicated for the treatment of malaria, discoid and systemic lupus erythematosus, and rheumatoid arthritis.

  

• HYQVIA for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy, USA

  HYQVIA® can treat primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).

  

I

• Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer

  Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy.

  

• Iclusig (ponatinib) for the Treatment of Chronic Myeloid Leukaemia

  Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered, developed and marketed by Ariad Pharmaceuticals.

  

• Idelvion for the Treatment of Haemophilia B

  Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) is an injectable formulation developed by CSL Behring, for the treatment of haemophilia B in children and adults.

  

• Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

  Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).

  

• Idraparinux – Investigational Agent for Treatment and Prevention of Thromboembolic Events

  The product of a joint development programme between Sanofi-Aventis (formerly Sanofi-Synthelabo) and Organon, Idraparinux is a new addition to the family of anticoagulant drugs.

  

• Ilaris (canakinumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis

  Ilaris (canakinumab) is a subcutaneous injection indicated for the treatment of systemic juvenile idiopathic arthritis (SJIA).

  

• Iloperidone – Atypical Antipsychotic for Schizophrenia

  Iloperidone is a dual-acting dopamine and serotonin receptor antagonist, developed originally by Titan Pharmaceuticals a

  

• Iluvien for the Treatment of Diabetic Macular Oedema

  Iluvien is indicated for the treatment of diabetic macular oedema, an eye disease that affects the retina.

  

• Imbruvica (Ibrutinib) for the Treatment of Mantle Cell Lymphoma (MCL)

  Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) patients that previously received at least one therapy.

  

• IMCIVREE (setmelanotide) for Chronic Weight Management in Bardet-Biedl Syndrome Patients, USA

  IMCIVREE® (setmelanotide) is the first approved treatment for managing weight in Bardet-Biedl syndrome patients.

  

• IMDELLTRA (tarlatamab) for the Treatment of Extensive-Stage Small Cell Lung Cancer, USA

  IMDELLTRA™ (tarlatamab) is the first T-cell engager therapy approved to treat extensive-stage small cell lung cancer (ES-SCLC).

  

• Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

  Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC).

  

• Imlygic (talimogene laherparepvec) for the Treatment of Cutaneous, Subcutaneous and Nodal Lesions

  Developed by Amgen, Imlygic (talimogene laherparepvec) is the first injectable formulation of altered herpes simplex virus type 1 for the treatment of cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrence after initial surgery.

  

• Inbrija for the Treatment of OFF Episodes in Parkinson’s Disease, USA

  Inbrija is indicated for OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa medicine.

  

• INCB9471 – CCR5 Antagonist for Treatment of HIV Infection

  Under development by Incyte Corporation, INCB9471 is an experimental small molecule drug indicated for the treatment of

  

• Incivek / Telaprevir – Treatment for Chronic Hepatitis C

  Incivek (telaprevir) is a protease inhibitor used for treating hepatitis C infections in liver patients.

  

• Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD)

  IncruseTM (unmeclidinium) Ellipta is the first approved anticholinergic indicated as a maintenance treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adult patients.

  

• Indinavir – First-Generation HIV Protease Inhibitor

  Merck's Crixivan (indinavir sulphate) is a first-generation HIV-protease inhibitor. Drugs such as indinavir have demonst

  

• Influenza A (H1N1) Monovalent Vaccine by Sanofi Pasteur

  Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine for 2009 Influenza A (H1N1) or swine flu is one of the f

  

• Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

  Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).

  

• INMAZEB for the Treatment of Zaire Ebolavirus Infection

  INMAZEB™ (atoltivimab, maftivimab, and odesivimab) is the first antiviral antibody therapeutics approved for the treatment of Zaire ebolavirus infection in adults and children, including newborns whose mothers tested positive for the infection.

  

• Inspra (Eplerenone)

  Inspra (eplerenone) is indicated for the treatment of chronic heart failure. It was developed by Pharmacia Corporation,

  

• Intermezzo – Treatment for Insomnia

  Intermezzo is a formulation of zolpidem that is indicated for the treatment of insomnia or sleeping disorders. The drug

  

• Invega Hafyera (paliperidone palmitate) for the Treatment of Schizophrenia

  Invega Hafyera™ (paliperidone palmitate) is a long-acting atypical antipsychotic drug indicated for the treatment of schizophrenia.

  

• Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia

  Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia .

  

• Invokamet XR for the Treatment of Type 2 Diabetes in Adults

  Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults.

  

• Invokana (canagliflozin) for the Treatment of Type 2 Diabetes

  Invokana (canagliflozin) is indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. It was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.

  

• Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia

  Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients.

  

• Iqirvo for the Treatment of Primary Biliary Cholangitis, US

  Iqirvo is available for oral administration as round, orange-coloured, film-coated tablets in a dosage strength of 80mg.

  

• Istaroxime

  Istaroxime is an investigational drug for acute decompensated heart failure under development by Debiopharm of Switzerla

  

• Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

  Isturisa® (osilodrostat) is the first cortisol synthesis inhibitor indicated for the treatment of Cushing's disease in adult patients, who are ineligible or failed pituitary surgery.

  

• Iwilfin for the Treatment of High-Risk Neuroblastoma, US

  Iwilfin is the first and only oral maintenance therapy for high-risk neuroblastoma approved by the FDA.

  

• Ixempra (Ixapebilone) chemotherapeutic agent – New Cancer Therapy

  Bristol-Myers Squibb's (BMS) ixabepilone (epothilone B) is a new chemotherapeutic agent that is currently in development

  

• Ixinity for Treatment for Haemophilia B

  Ixinity (coagulation factor IX (recombinant)) is an intravenous injection containing recombinant human coagulation factor IX that is indicated for the control and prevention of bleeding episodes in patients suffering from haemophilia B.

  

• Izervay for the Treatment of GA, US

  Izervay is available as a clear to slightly opalescent, colourless to slightly yellow solution.

  

J

• Jakafi (ruxolitinib) – Treatment of Myelofibrosis

  Jakafi (ruxolitinib) is an oral janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis. It was developed by Incyte Corp in collaboration with Novartis.

  

• Januvia – Treatment of Diabetes Type 2

  Januvia (sitagliptin phosphate) is an antihyperglycaemic drug containing an orally active inhibitor of the dipeptidyl pe

  

• Jardiance (empagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF)

  Jardiance® (empagliflozin) is an SGLT2 inhibitor indicated to treat heart failure in adults with reduced ejection fraction.

  

• Jardiance for the Treatment of Type 2 Diabetes, US

  Jardiance is available as a film-coated, pale-yellow-coloured tablet in 10mg and 25mg strengths for oral administration.

  

• Jaypirca (pirtobrutinib) for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, USA

  Jaypirca™ is a first-of-a kind BTK inhibitor for the treatment of mantle cell lymphoma in previously treated patients.

  

• Jemperli (dostarlimab-gxly) for the Treatment of Advanced Solid Tumours, US

  Jemperli is the first anti-PD-1 therapy for the treatment of certain types of endometrial cancer in Europe.

  

• Jesduvroq (daprodustat) for the Treatment of Anaemia of Chronic Kidney Disease on Dialysis, USA

  Jesduvroq (daprodustat) is the first oral treatment for anaemia caused by chronic kidney disease in adults undergoing dialysis.

  

• Jetrea (ocriplasmin) for Treatment of Symptomatic Vitreomacular Adhesion

  Jetrea (ocriplasmin) is a pharmacological agent developed by ThromboGenics, for the treatment of Symptomatic Vitreomacular Adhesion (VMA).

  

• Juluca (Dolutegravir and Rilpivirine) for the Treatment of HIV-1 Infection

  Juluca® (Dolutegravir and Rilpivirine) is a two-drug regimen indicated for the maintenance treatment of HIV-1 infection in adults.

  

• Juxtapid (lomitapide) for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

  Juxtapid (lomitapide) is developed and manufactured by Aegerion Pharmaceuticals for the treatment of patients affected with homozygous familial hypercholesterolemia (HoFH).

  

• JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

  

• JYNNEOS Vaccine for the Prevention of Smallpox and Monkeypox

  JYNNEOS™ is a non-replicating vaccine indicated for smallpox and monkeypox disease prevention in adults aged 18 years and older.

  

K

• Kadcyla (Trastuzumab Emtansine) for Treatment of Breast Cancer

  Kadcyla (trastuzumab emtansine) is an antibody drug conjugate indicated for the treatment of HER2-positive metastatic breast cancer (mBC). The drug has been developed by Genentech (a member of the Roche Group).

  

• Kalbitor – Treatment for Hereditary Angioedema

  Kalbitor (ecallantide) is a drug developed by US-based Dyax Corp for the treatment of hereditary angioedema (HAE).

  

• Kalydeco (Ivacaftor) – Treatment for Cystic Fibrosis

  Kalydeco (Ivacaftor / VX-770) is a cystic fibrosis transmembrane conductor regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF).

  

• KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies

  KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma.

  

• Kanuma (sebelipase alfa) for the Treatment of Lysosomal Acid Lipase Deficiency (LAL-D)

  Kanuma™ (sebelipase alfa) is an enzyme replacement therapy (ERT) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D).

  

• Kengreal (cangrelor) for Reducing Thrombotic Events During Percutaneous Coronary Intervention (PCI)

  Kengreal (cangrelor) is the first and only intravenous anti-platelet agent indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing thrombotic events.

  

• KERENDIA (finerenone) for the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes, USA

  KERENDIA® is the first, nonsteroidal mineralocorticoid receptor antagonist for diabetes-related chronic kidney disease.

  

• Kesimpta (ofatumumab) for the Treatment of Relapsing Multiple Sclerosis (RMS)

  Kesimpta® (ofatumumab) is the first and only self-administered, targeted B-cell therapy indicated for the treatment of patients with relapsing multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active secondary progressive multiple sclerosis (SPMS).

• Keveyis for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis

  Keveyis (dichlorphenamide) is the first medicine indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, which are a group of rare hereditary disorders that cause occasional episodes of muscle weakness or paralysis.

  

• Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis

  Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

  

• Keytruda (pembrolizumab) for the treatment of metastatic melanoma

  Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) immunotherapy developed by Merck to treat melanoma.

  

• Kineret (anakinra) for the Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

  Kineret (anakinra) is a recombinant protein drug which was originally discovered and developed by Amgen. The drug was later licensed to Swedish Orphan Biovitrum (Sobi) in December 2008.

  

• Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

  Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.

  

• Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, USA

  Kisunla™ (donanemab-azbt) is an amyloid plaque-targeting therapy, developed by Eli Lilly, to treat early Alzheimer's disease.

  

• Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome

  Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome.

  

• Korsuva (difelikefalin) for the Treatment of Pruritus Associated with Chronic Kidney Disease

  Korsuva (difelikefalin) is the first US FDA-approved treatment for moderate-to-severe pruritus in adult patients on haemodialysis.

  

• Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)

  Koselugo® (selumetinib) is the first FDA-approved drug indicated for the treatment of neurofibromatosis type 1 (NFI), a rare and incurable genetic condition, developed and commercialised globally by AstraZeneca and Merck (MSD) under a licensing agreement.

  

• Kovaltry (Anti-haemophilic Factor VII (Recombinant)) for the Treatment of Haemophilia A

  Kovaltry (Anti haemophilic Factor VII (Recombinant)) is developed by Bayer as the treatment for children and adult patients with haemophilia A.

  

• Krazati (adagrasib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC), USA

  Krazati™ (adagrasib) is a targeted treatment for advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation.

  

• KRX-0401 Perifosine

  KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed

  

• Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia, USA

  Kymriah (tisagenlecleucel) is the first FDA-approved CAR-T therapy indicated for treating ALL.

  

• KYNMOBI for the Treatment of OFF episodes in Parkinson’s Disease, USA

  KYNMOBI is the first and only sublingual therapy indicated for the on-demand treatment of OFF episodes in Parkinson's disease.

  

• Kyprolis (carfilzomib) for Treatment of Multiple Myeloma

  Kyprolis (carfilzomib), developed and manufactured by Onyx Pharmaceuticals, is a proteasome inhibitor indicated for the treatment of the patients with multiple myeloma.

  

L

• Lamictal – Approved Treatment for Epilepsy and Bipolar

  Lamictal XR (lamotrigine), developed by GlaxoSmithKline, is an approved treatment for epilepsy and bipolar I disease. Th

  

• Lampit (nifurtimox) for the Treatment of Chagas Disease

  Lampit® (nifurtimox) is an antiprotozoal medication indicated for the treatment of Chagas disease (American Trypanosomiasis) in paediatric patients from birth to less than 18 years of age and weighing at least 2.5kg.

  

• Lamzede (velmanase alfa) to Treat Alpha-Mannosidosis

  Lamzede® (velmanase alfa) is one of the first enzyme replacement therapies indicated for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha‑mannosidosis.

  

• Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma

  Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.

  

• Latuda (lurasidone HCl) for the Treatment of Schizophrenia

  Latuda (lurasidone HCl) is indicated for the treatment of schizophrenia. The drug was developed by Sunovion Pharmaceut

  

• Lenvima™ (Lenvatinib Mesylate) for the Treatment of Thyroid Cancer

  Lenvima™ (lenvatinib mesylate) is a multiple receptor tyrosine kinase (RTK) inhibitor indicated for the treatment of thyroid cancer.

  

• Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, USA

  Leqembi™ is the second FDA-approved anti-amyloid antibody for Alzheimer disease, after Biogen’s aducanumab.

  

• Leqvio for the Treatment of Hypercholesterolaemia, US

  Patients need to be administered two maintenance doses of the drug a year via syringe, following an initial dose and another at three months.

  

• Lexapro – Treatment of Major Depressive Disorder in Adolescents

  In March 2009, the US Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) of Forest

  

• Libtayo (cemiplimab-rwlc) for the Treatment of Advanced Non-Small Cell Lung Cancer

  Libtayo (cemiplimab-rwlc) is an advanced fully human monoclonal antibody indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients ineligible to undergo curative surgery or radiation therapy.

  

• Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis

  Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and La

  

• Linzess (linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation, USA

  Linzess (linaclotide) is a guanylate cyclase-C (GC-C) receptor agonist co-developed by AbbVie and Ironwood Pharmaceuticals.

  

• Lipaglyn (Saroglitazar) for Treating Hypertriglycerdaemia in Type 2 Diabetes, India

  Lipaglyn (saroglitazar) is approved for the treatment of hypertriglyceridaemia in type 2 diabetes.

  

• Lipitor (Atorvastatin) – Treatment for High Cholesterol

  Lipitor (Atorvastatin) is a statin class drug indicated for reducing high cholesterol levels in the blood, which helps prevent cardiovascular diseases. It is manufactured by Pfizer.

  

• Lipitor / Torcetrapib – Combination Therapy

  Under development by Pfizer, torcetrapib is a member of the cholesteryl ester transfer protein (CETP) inhibitor class of

  

• Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia

  Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder.

  

• Liraglutide – Next-Generation Antidiabetic Medication

  Under development by Novo Nordisk, liraglutide is a member of a new class of antidiabetic medications called GLP-1 analo

  

• Livdelzi (Seladelpar) for the Treatment of Primary Biliary Cholangitis, USA

  Livdelzi® (seladelpar) received accelerated approval from the US FDA in August 2024 for treating primary biliary cholangitis.
  

  

• Livmarli™ (maralixibat) for the Treatment of Cholestatic Pruritus in Alagille Syndrome

  Livmarli™ (maralixibat) is the first and only approved treatment for cholestatic pruritus in patients with Alagille syndrome.

  

• Livtencity (maribavir) for the Treatment of Post-Transplant Cytomegalovirus (CMV) Infection, USA

  Livtencity™ is the first and only treatment for post-transplant cytomegalovirus infection in adult and paediatric patients.

  

• Lixisenatide

  Lixisenatide is an investigational glucagon-like peptide (GLP)-1 agonist being developed for the treatment of type 2 d

  

• LODOCO (colchicine) for the Treatment of Cardiovascular Disease, USA

  LODOCO® (colchicine) is the first FDA-approved anti-inflammatory atheroprotective cardiovascular treatment.
  

  

• LODOTRA – Treatment for Rheumatoid Arthritis

  Lodotra was developed utilising SkyePharma's proprietary GeoClock and GeoMatrix technologies, for which Horizon Pharma holds an exclusive worldwide license for the delivery of corticosteroids.

  

• Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia

  Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.

  

• Lonsurf (trifluridine and tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

  Lonsurf is approved for the treatment of patients with advanced metastatic colorectal cancer (mCRC).

  

• Loqtorzi for the Treatment of Nasopharyngeal Carcinoma, US

  Loqtorzi is the first and only treatment approved by the FDA for the first-line treatment of nasopharyngeal carcinoma.
  

  

• Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer

  Lorbrena® (lorlatinib) is an anaplastic lymphoma kinase (ALK) inhibitor indicated as a second or third-line treatment of advanced non-small cell lung cancer (NSCLC). The drug was discovered and developed by Pfizer.

• Lorcaserin, Investigational Oral Anti-Obesity Drug

  Lorcaserin hydrochloride (Lorcaserin) is an investigative oral treatment drug for obesity, and was discovered by Arena P

  

• Lovenox (Enoxaparin Sodium) – Treatment for Deep Vein Thrombosis (DVT)

  Lovenox (enoxaparin sodium) is an anti-thrombotic drug indicated for the treatment of deep vein thrombosis (DVT) and acute ST-segment elevation myocardial infarction (STEMI).

  

• Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms

  Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.

  

• Lucentis (ranibizumab) for the Treatment of Diabetic Macular Edema (DME)

  Lucentis (ranibizumab) is a monoclonal antibody indicated for the treatment of diabetic macular edema (DME). The drug is developed by Genentech, a subsidiary of Roche Group.

  

• LUMAKRAS (sotorasib) for the Treatment of Non-Small Cell Lung Cancer

  LUMAKRAS (sotorasib) is approved in the US, United Arab Emirates (UAE), Canada and the UK.

  

• Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia

  Lumoxiti (Moxetumomab pasudotox) is an investigational anti-CD22 recombinant immunotoxin developed as a potential treatment for relapsed/refractory hairy cell leukaemia (HCL) patients previously treated with at least two lines of therapy.

  

• LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US

  LUPKYNIS™ (voclosporin) is a calcineurin-inhibitor immunosuppressant indicated for the treatment of adult patients with active lupus nephritis (LN).

  

• Lurasidone – Treatment for Schizophrenia and Bipolar Disorder

  Lurasidone is an atypical antipsychotic agent developed by Japan's Dainippon Sumitomo Pharma (DSP). The drug is indicat

  

• Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours

  Lutathera® (lutetium Lu 177 dotatate) is a peptide receptor radionuclide therapy (PRRT) indicated for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

  

• Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy

  LuxturnaTM (voretigene neparvovec) is approved for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.

  

• LY2140023 – Treatment of Schizophrenia

  Under development by Eli Lilly, LY2140023 is a novel investigational agent for the treatment of schizophrenia. A member

  

• Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder

  Lybalvi® is a prescription medicine indicated for the treatment of adults with schizophrenia and bipolar I disorder.

  

• Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer

  Lynparza (olaparib), discovered and developed by AstraZeneca, is the first PARP inhibitor drug approved for germline BRCA-mutated advanced ovarian cancer.

  

• Lyrica (Pregabalin) for the Treatment of Neuropathic Pain, USA

  Lyrica is a 3-substituted analogue of gamma-aminobutyric acid indicated to treat neuropathic pain.

  

• Lyumjev (insulin lispro-aabc) for the Treatment of Type 1 and Type 2 Diabetes

  Lyumjev™ (insulin lispro-aabc) is rapid-acting insulin indicated to enhance glucose control in adults with type 1 and type 2 diabetes.

  

M

• M6G, A New Morphine Derivative For Post-Operative Pain Relief

  Morphine-6-Glucuronide (M6G) is a new morphine derivative under development by biopharmaceutical company PAION. Developm

  

• Maraviroc – Therapy for Treatment of HIV Infection

  Discovered and developed by researchers at Pfizer, maraviroc is a novel treatment for infection due to the human immunod

  

• Mavenclad (cladribine tablets) for the Treatment of Relapsing-Remitting Multiple Sclerosis

  Mavenclad™ (cladribine tablets) is a selective immune reconstitution therapy indicated for the treatment of active relapsing multiple sclerosis.

  

• MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

  MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).

  

• Mayzent for the Treatment of Multiple Sclerosis, US

  The drug has been approved by governmental health departments in the US, Japan, Europe, and Canada.

  

• Mekinist (Trametinib) – Treatment for Metastatic Melanoma

  Mekinist (trametinib) is a mitogen-activated protein kinase (MEK) inhibitor indicated for the treatment of unresectable or metastatic melanoma in adult patients.

  

• Menactra – Meningococcal Vaccine

  Menactra vaccine is developed and manufactured by Sanofi Pasteur, the vaccines division of the Sanofi Aventis Group. The

  

• Menveo vaccine for the prevention of invasive meningococcal disease

  Menveo is an active immunisation vaccine indicated for the prevention of invasive meningococcal disease caused by sero

  

• Merck Isentress – Emerging Therapy for Treatment of HIV Infection

  Under development by Merck & Co, Isentress (raltegravir) is an experimental drug indicated for the treatment of human im

  

• Mirapex (Pramipexole Dihydrochloride) for the Treatment of Parkinson’s Disease, USA

  Mirapex is indicated to treat Parkinson’s disease (PD) symptoms and restless legs syndrome (RLS).

  

• Monovisc (sodium hyaluronate) for the Treatment of Osteoarthritis

  Monovisc (sodium hyaluronate), indicated for the treatment of Osteoarthritis (OA) of the knee, is the first US Food and Drug Administration (FDA) approved single injection made with hyaluronate from a non-animal source.

  

• MOR103 – Antibody for the Treatment of Rheumatoid Arthritis

  MOR103 is a fully human antibody indicated for the treatment of rheumatoid arthritis (RA). The drug is being developed

  

• Motavizumab – New Biological Therapy for RSV Prevention

  Developed by MedImmune (now wholly owned by AstraZeneca), motavizumab is an investigational monoclonal antibody (MAb) in

  

• Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA

  Mounjaro™ (tirzepatide) is a first-in-class GIP and GLP-1 receptor agonist for treating type 2 diabetes.

  

• Movantik for the Treatment of Opioid-Induced Constipation

  Movantik™ (naloxegol) is an opioid antagonist therapy indicated for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.

  

• Multaq

  Multaq (dronedarone) is a Class III antiarrhythmic drug developed by Sanofi-Aventis (formerly Sanofi-Synthlelabo) for th

  

• Myalepta (metreleptin) for the Treatment of Lipodystrophy

  Myalepta® (metreleptin) is a recombinant human leptin analogue indicated to treat complications of congenital or acquired generalised lipodystrophy.

  

• Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

  Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.

  

• Mylinax – Novel Therapy for the Treatment of

  The product of a joint development programme between IVAX Corporation and Serono, Mylinax, a proprietary oral formulatio

  

• Myobloc (rimabotulinumtoxinB) for the Treatment of Chronic Sialorrhea

  Myobloc® (rimabotulinumtoxinB) is the first neurotoxin approved for the treatment of chronic sialorrhea in adults.

  

• Myrbetriq (Mirabegron) – Treatment for Overactive Bladder (OAB)

  Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of the overactive bladder (OAB) condition. It was developed by Japan's Astellas Pharma.

  

N

• Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer’s Disease

  Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US.

  

• Naproxcinod (HCT 3012) – COX-Inhibiting Nitric Oxide-Donator

  Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012) is the first in a new class of analgesic and an

  

• Natesto Nasal Gel for the Treatment of Men with Low Testosterone

  Natesto (testosterone, formerly known as CompleoTRT) is the only FDA-approved nasal gel for treatment of adult males with conditions associated with deficiency or absence of endogenous testosterone.

  

• Natpara® (parathyroid hormone) for the Treatment of Hypoparathyroidism

  Natpara® (parathyroid hormone), a subcutaneous injection indicated for the treatment of hypoparathyroidism, was discovered and developed by NPS Pharmaceuticals that was acquired by Shire in February 2015.

  

• Nerlynx (neratinib) for the Treatment of Breast Cancer

  Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer.

  

• Nesina (alogliptin) for Treatment of Type 2 Diabetes Mellitus

  Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed and marketed by Takeda Pharmaceuticals for the treatment of diabetes 2 mellitus.

  

• Nexavar for Kidney or Liver Cancer

  Nexavar is an oral anti-cancer agent that blocks cell proliferation and tumour angiogenesis. Developed by Bayer Healthcare with Onyx Pharmaceuticals, the drug obstructs the receptor tyrosine kinases – vascular endothelial growth factor receptor (VEGFR) VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR B), KIT, fms-related tyrosine kinase 3 (FLT-3) and RET – along the signalling pathways.

  

• Nexium I.V.- Treatment of Gastroesophageal Reflux Disease

  Nexium I.V. (intravenous) / esomeprazole sodium is a proton pump inhibitor manufactured and marketed by Astra Zeneca fo

  

• NEXLETOL (bempedoic acid) for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH), USA

  NEXLETOL® (bempedoic acid) and its combination with ezetimibe NEXLIZET® are oral non-statin cholesterol-lowering drugs.

  

• Nexviazyme (avalglucosidase alfa-ngpt) for the Treatment of Late-onset Pompe Disease

  Nexviazyme® (avalglucosidase alfa-ngpt) is a new therapeutic option approved for the treatment of late-onset Pompe disease.

  

• NG2-73 – A Novel Agent For The Treatment of Insomnia

  Under development by specialist pharmaceutical company, Neurogen, NG2-73 is a new, selective gamma-amino butyric acid (G

  

• NGENLA (somatrogon) for the Treatment of Paediatric Growth Hormone Deficiency, USA

  NGENLA® (somatrogon) is a human growth hormone analogue to treat growth failure in children aged three years and older.

  

• NicVAX for Nicotine Addiction

  NicVAX is an investigational vaccine developed for use as an aid to treat smoking addiction and prevent smoking relaps

  

• NIKTIMVO for the Treatment of cGvHD, US

  NIKTIMVO received US FDA approval in August 2024 to treat GvHD.
  
  

  

• Ninlaro (ixazomib) for the Treatment of Multiple Myeloma

  Ninlaro (ixazomib) is a proteasome inhibitor indicated for the treatment of multiple myeloma.

  

• Northera (droxidopa) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (NOH)

  Northera (droxidopa) is the world’s first approved therapy for symptomatic neurogenic orthostatic hypotension (NOH).

  

• NOURIANZ (istradefylline) for the Treatment of Parkinson’s Disease

  NOURIANZ (istradefylline) is indicated as adjunctive therapy to levodopa and carbidopa medications in adult patients with Parkinson’s disease (PD) to treat “off” episodes, caused when existing medications are ineffective and lead to an increase in PD symptoms.

  

• Novavax Trivalent VLP Vaccine for Seasonal Influenza

  Novavax's trivalent seasonal influenza virus-like particle (VLP) vaccine was developed to address the need to produce va

  

• Noxafil (posaconazole) for the Treatment of Fungal Infections

  Noxafil (posaconazole) is a triazole antifungal agent indicated for treatment of the prophylaxis of invasive Aspergillus and Candida infections.

  

• Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES)

  Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients aged 12 years and older.

  

• Nuedexta for the Treatment of Pseudobulbar Affect (PBA)

  Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) is a combination drug indicated for the treatment of pseudobulbar affect (PBA). The drug was developed and manufactured by Avanir Pharmaceuticals.

  

• Nulibry™ (Fosdenopterin) for the Treatment of Molybdenum Cofactor Deficiency Type A

  Nulibry™ (fosdenopterin) is the first and only US Food and Drug Administration (FDA) approved treatment indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

  

• Nulojix – Treatment for Preventing Acute Organ Rejection Post Kidney Transplantation

  Nulojix (Belatacept) was developed by Bristol Myers Squibb and is indicated to prevent the rejection of the organ in p

  

• Nuplazid (pimavanserin) for the Treatment of Parkinson’s Disease Psychosis (PDP), USA

  Nuplazid (pimavanserin) is an atypical antipsychotic drug indicated for the treatment of Parkinson’s disease psychosis (PDP).

  

• NURTEC (Rimegepant) for the Acute Treatment of Migraine

  NURTEC® ODT (rimegepant) is the first migraine medication indicated for both acute and preventive treatment in adults.

  

• Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A

  Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A.

  

• Nymalize (nimodipine) for the Treatment of Subarachnoid Haemorrhage (SAH)

  Nymalize (nimodipine) is an oral liquid form capsule indicated to improve neurological outcomes in patients suffering from subarachnoid haemorrhage (SAH).

  

O

• Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A

  Obizur antihemophilic factor (recombinant) is the first recombinant porcine FVIII indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).

  

• Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis

  Developed by Genentech, Ocrevus (ocrelizumab) is indicated for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS.

  

• Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma

  Odomzo® (sonidegib) is an oral, selective smoothened (SMO) inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). The drug was discovered and developed by Novartis.

  

• Ofev (nintedanib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  Discovered and developed by German pharmaceutical company Boehringer Ingelheim, Ofev (nintedanib) is the first and only tyrosine kinase inhibitor (TKI) to receive approval for the treatment of idiopathic pulmonary fibrosis (IPF).

  

• Ogsiveo for the Treatment of Desmoid Tumours, US

  The Phase III DeFi clinical trial for Ogsiveo demonstrated both clinically meaningful and statistically significant improvements.

  

• Ohtuvayre (ensifentrine) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD), USA

  Ohtuvayre™ (ensifentrine) is a novel, inhaled treatment for adult patients with chronic obstructive pulmonary disease (COPD).

  

• OJEMDA (tovorafenib) for the Treatment of Paediatric Low-Grade Glioma (pLGG), USA

  OJEMDA™ (tovorafenib) is the first and only FDA-approved medicine for children with BRAF fusions or rearrangements.
  

  

• Olcegepant – Novel Therapy for Acute Migraine

  Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP)

  

• OLINVYK (oliceridine) for the Treatment of Acute Pain

  OLINVYK™ (oliceridine) is a new chemical agent indicated for the treatment of acute pain in adults for whom the available treatments are ineffective.

  

• Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

  Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).

  

• Olysio (simeprevir) for the Treatment of Chronic Hepatitis C (CHC)

  Olysio (simeprevir) is an antiviral drug indicated for the treatment of chronic hepatitis C (CHC) infection.

  

• Omidria™ for Use in Cataract and Other Intraocular Lens Replacement (ILR) Procedures

  Omidria (ketorolac and phenylephrine/ OMS302) is the only approved drug for intraocular use to prevent intraoperative miosis and reduce postoperative pain in cataract surgery and other intraocular lens replacement (ILR) procedures.

  

• Omontys (peginesatide) – for Treatment of Anaemia Associated with Chronic Kidney Disease

  Omontys (peginesatide) is an erythropoiesis-stimulating agent (ESA) developed for the treatment of anaemia associated with chronic kidney disease (CKD).

  

• Omvoh (mirikizumab-mrkz) for the Treatment of Active Ulcerative Colitis, USA

  Omvoh™ is a biologic treatment approved for moderate to severe active ulcerative colitis (UC) in adults.

  

• Onbrez Capsules – Treatment for Chronic Obstructive Pulmonary Disease

  Onbrez capsules are hard capsules developed by Novartis for the treatment of chronic obstructive pulmonary disease (CO

  

• Onfi (Clobazam) – Treatment for Lennox-Gastaut Syndrome

  Onfi (clobazam) is an antiepileptic drug approved to treat seizures that are associated with Lennox-Gastaut syndrome (LGS) in patients who are aged two years and above.

  

• ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease

  ONGENTYS® (opicapone) is the first and only approved catechol-O-methyltransferase (COMT) inhibitor indicated for the treatment of Parkinson's disease with off episodes, used as an adjunctive treatment to levodopa and carbidopa.

  

• Onivyde (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

  Onivyde (MM-398 / irinotecan liposome injection) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.

  

• Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

  Onpattro™ (patisaran) is the first-of-its-kind RNA interference (RNAi)-based drug indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

  

• ONUREG (azacitidine) for the Treatment of Acute Myeloid Leukaemia (AML)

  ONUREG® (azacitidine) is the first and only US Food and Drug Administration (FDA)-approved drug indicated for the continued treatment of acute myeloid leukaemia (AML) in adult patients.

  

• ONZETRA Xsail for the Treatment of Migraine in Adults

  ONZETRA Xsail is a Food and Drug Administration (FDA)-approved intranasal dry powder formulation developed by Avanir Pharmaceuticals.

  

• Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma

  Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progression with Yervoy (ipilimumab).

  

• Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Unresectable or Metastatic Melanoma, USA

  Opdualag™ (nivolumab and relatlimab-rmbw) is indicated for the treatment of unresectable or metastatic melanoma.

  

• Opsumit (Macitentan) for Treatment of Pulmonary Arterial Hypertension (PAH)

  Opsumit (macitentan) is an oral dual endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH).

  

• Opzelura (ruxolitinib) for the Treatment of Vitiligo, US

  Opzelura (ruxolitinib) is the first and only topical treatment for repigmentation in vitiligo patients to have been approved by the Food and Drug Administration (FDA).

  

• Oral-Lyn – Oral Spray Formulation of Human Insulin for Types 1 and 2 Diabetes

  Oral-Lyn is an oral spray formulation of human insulin indicated for the treatment of type 1 and 2 diabetes. It is being

  

• Orbactiv (oritavancin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

  Orbactiv (oritavancin) is the first and only approved antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.

  

• Orenitram (treprostinil) for Treatment of Pulmonary Arterial Hypertension (PAH)

  Orenitram (treprostinil/UT-15C) is indicated for the treatment of pulmonary arterial hypertension (PAH), in World Health Organisation (WHO) Group I patients, to improve exercise capacity.

  

• ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer

  ORGOVYX™ (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer in adult patients.

  

• ORILISSA (elagolix) for the Treatment of Pain Associated with Endometriosis

  ORILISSA (elagolix) is an oral gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of moderate-to-severe pain associated with endometriosis.

  

• Oritavancin – Glycopeptide Antibiotic

  Oritavancin is an investigational glycopeptide antibiotic being developed by Targanta Therapeutics for the treatment of

  

• Orkambi (lumacaftor/ivacaftor) for the Treatment of Cystic Fibrosis (CF)

  Orkambi (lumacaftor/ivacaftor) is the first approved medicine to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease.

  

• ORLADEYO (berotralstat) for the Treatment of Hereditary Angioedema (HAE), USA

  ORLADEYO™ (berotralstat) is the first oral, once-daily preventive therapy indicated for hereditary angioedema (HAE).

  

• Orserdu (elacestrant) for the Treatment of Advanced or Metastatic Breast Cancer, USA

  Orserdu™ is the first endocrine therapy for ESR1-mutated advanced or metastatic breast cancer in more than two decades.

  

• Osanetant – Novel Investigational Agent for Treatment of Schizophrenia

  Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was

  

• Otezla (apremilast) for the Treatment of Active Psoriatic Arthritis

  Otezla (apremilast), developed by Celgene Corporation, is an inflammatory drug indicated for the treatment of adult patients with active psoriatic arthritis (PsA).

  

• Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

  Oxbryta™ (voxelotor), previously known as GBT440, is the first and only FDA-approved sickle haemoglobin polymerisation inhibitor indicated for the treatment of sickle cell disease (SCD).

  

• Oxervate (cenegermin-bkbj) to Treat Neurotrophic Keratitis, US

  Oxervate™ (cenegermin-bkbj) is an ophthalmic solution indicated for the treatment of moderate-to-severe neurotrophic keratitis.

  

• OXLUMO (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

  OXLUMO™ (lumasiran) is the first small interfering ribonucleic acid (RNAi) therapeutics indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary oxalate levels in paediatric and adult patients.

  

• Oxtellar XR for the Treatment of Partial Seizures

  Oxtellar XR (oxcarbazepine/ SPN-804) is an anti-epileptic drug indicated for the treatment of partial seizures. The drug is developed, manufactured and marketed by Supernus Pharmaceuticals.

  

• Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women

  Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency.

  

• Ozempic (semaglutide) for the Treatment of Type 2 Diabetes

  Ozempic® (semaglutide) is a glucagon-like peptide (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes in adults.

  

P

• Padcev (enfortumab vedotin) for the Treatment of Urothelial Cancer, USA

  Padcev (enfortumab vedotin) is the first Nectin-4-directed antibody-drug conjugate approved to treat urothelial cancer.

  

• Palynziq (pegvaliase-pqpz) for the Treatment of Phenylketonuria

  Palynziq™ (pegvaliase-pqpz) is a subcutaneous infusion indicated for the treatment of adults with phenylketonuria (PKU).

  

• Pandemrix – Adjuvanted H1N1 Influenza Vaccine

  Pandemrix is an adjuvanted vaccine used in the prevention of the H1N1 (swine flu) virus infection and has been developed

  

• Panflu.1 – Single-Shot Vaccine Against H1N1 Influenza

  Developed by Sinovec Biotech to provide protection against the H1N1 virus, also known as swine flu, Panflu.1 is a single

  

• Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)

  Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.

  

• Paxil – SSRI for the Treatment of Major Depressive Disorders

  Paxil (paroxetine hydrochloride) was first developed in 1975 by a Danish company called Ferrosan. During 1980 Ferrosan s

  

• Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19

  Paxlovid is the first FDA-approved oral antiviral treatment for mild to moderate Covid-19 in adult and paediatric patients.

  

• Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma

  Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.

  

• PENBRAYA (Meningococcal A, B, C, W, and Y vaccine) for the Prevention of Meningococcal Disease, USA

  PENBRAYA™ is the first pentavalent vaccine to protect adolescents against the most common types of meningococcal disease.
  

  

• PEPAXTO® (melphalan flufenamide) for the Treatment of Multiple Myeloma

  PEPAXTO® (melphalan flufenamide) is a first-in-class peptide-drug conjugate indicated in combination with the glucocorticoid dexamethasone for the treatment of relapsed or refractory (r/r) multiple myeloma in adult patients.

  

• Pertuzumab – Treatment / Therapy for Breast Cancer

  Roche / Genentech's Perjeta (Pertuzumab) is a humanised monoclonal antibody (MAb) to the HER2 receptor for the treatment of advanced breast cancer.

  

• Phenserine – Next Generation AChE Inhibitor

  Axonyx, a US biopharmaceutical company that focuses on treatments for dementia, developed phenserine as a next-generatio

  

• Phesgo for the Treatment of HER2-Positive Breast Cancer, US

  The formulation of Phesgo incorporates Halozyme Therapeutics’ Enhanze drug delivery technology.
  

  

• PiaSky (crovalimab) for the Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH), USA

  PiaSky® (crovalimab), discovered by Chugai, treats paroxysmal nocturnal haemoglobinuria (PNH) in adult and paediatric patients.

  

• Pifeltro (doravirine) for the Treatment of HIV-1 Infection

  Pifeltro (doravirine) is indicated for the treatment of adult patients with Human Immunodeficiency Virus-1 (HIV-1) infection.

  

• Piqray (alpelisib) for the Treatment of Advanced Breast Cancer

  Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.

  

• Pirfenidone – Treatment for Idiopathic Pulmonary Fibrosis

  Pirfenidone is a drug indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring and thickening of lungs.

  

• Plavix (Clopidogrel Bisulfate) – Treatment for Acute Coronary Syndrome

  Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor indicated for the treatment of acute coronary syndrome (ACS).

  

• Plectasin NZ2114 – Novel Microbial Agent

  Under development by Novozymes A/S, the Danish biotechnology company, plectasin NZ2114 is a novel antimicrobial peptide.

  

• Plegridy (peginterferon beta-1a) for the Treatment of Relapsing Multiple Sclerosis (RMS)

  Plegridy (peginterferon beta-1a) is the only pegylated beta interferon approved for the treatment of relapsing multiple sclerosis (RMS). The drug was discovered and developed by Biogen Idec.

  

• Pluvicto for the treatment of metastatic castration-resistant prostate cancer

  Pluvicto™ is the first FDA-approved targeted radioligand therapy for PSMA+ metastatic, castration-resistant prostate cancer.

  

• Polivy (polatuzumab vedotin) for the Treatment of Diffuse Large B-cell Lymphoma

  Polivy™ (polatuzumab vedotin-piiq) is an antibody-drug conjugate indicated for the third-line treatment of adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

  

• Pomalyst (Pomalidomide) for the Treatment of Multiple Myeloma

  Pomalyst (pomalidomide) is an anti-angiogenic drug developed by Celgene Corporation for the treatment of multiple myeloma in patients who have received two prior therapies.

  

• PONVORY (ponesimod) for the Treatment of Multiple Sclerosis

  PONVORY™ (ponesimod) is an oral disease-modifying therapy approved for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).

  

• Portrazza (necitumumab) for the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

  Portrazza (necitumumab) is a recombinant human lgG1 monoclonal antibody developed by Eli Lilly, for the treatment of metastatic squamous non-small cell lung cancer (NSCLC).

  

• POSLUMA (flotufolastat F 18) PET Imaging Agent for Prostate Cancer, USA

  POSLUMA® is the first FDA-approved radio-hybrid PSMA-targeted agent for PET imaging of prostate cancer in adults.

  

• Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome

  Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.

  

• Pradaxa (dabigatran etexilate) – Oral Direct Thrombin Inhibitor

  Pradaxa (dabigatran etexilate) is an oral anticoagulant under development by Boehringer Ingelheim. Its primary indicatio

  

• Praluent (alirocumab) for the Treatment of Hypercholesterolemia

  Praluent (alirocumab) is an investigational therapy injection intended for the treatment of patients with hypercholesterolemia.

• Prasugrel, Investigational Antiplatelet Agent by Daiichi Sankyo and Lilly

  Originally discovered by Sankyo and Ube Industries, prasugrel is now the product of a co-development programme between D

  

• Prexige – COX-2 Inhibitor

  Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by Novartis for the relief of pain and inflammation ass

  

• Prezcobix™ (darunavir/cobicistat) for the Treatment of HIV-1

  Prezcobix™ (darunavir / cobicistat), discovered and developed by Janssen Therapeutics, is a fixed-dose antiretroviral combination tablet indicated for the treatment of human immunodeficiency virus (HIV-1) infection.

  

• PRIORIX for the Prevention of Measles, Mumps and Rubella, USA

  The PRIORIX vaccine is approved for the prevention of measles, mumps and rubella (MMR) in people aged 12 months and older.

  

• Procysbi (cysteamine bitartrate) for the Treatment of Nephropathic Cystinosis

  Procysbi (cysteamine bitartrate) is a delayed-release capsule indicated for the treatment of nephropathic cystinosis. The drug was discovered and developed by Raptor Pharmaceutical (Raptor).

  

• Prolia (Denosumab) – Therapy for Prevention and Treatment of Osteoporosis

  Amgen's prolia (denosumab) is a biological therapy developed for the prevention and treatment of osteoporosis and other

  

• Promacta (eltrombopag) for the Treatment of Severe Aplastic Anaemia (SAA)

  Promacta (eltrombopag) is the first-in-class treatment indicated for patients with severe aplastic anaemia (SAA) immunosuppressive therapy (IST) was proven ineffective for.

  

• Provenge – Treatment for Advanced Prostate Cancer

  Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate cancer.

  

• PSI-7977 for Treatment of Chronic Hepatitis C

  PSI-7977 is indicated for the treatment of chronic Hepatitis C-virus (HCV) infection. The investigational drug is being

  

Q

• QALSODY (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis, Europe

  QALSODY® (tofersen) is the first therapy approved for a rare, genetic form of amyotrophic lateral sclerosis (ALS).

  

• QINLOCK (ripretinib) for the Treatment of Gastrointestinal Stromal Tumour

  QINLOCK™ (ripretinib) is indicated as a fourth-line treatment for advanced gastrointestinal stromal tumour (GIST) in adult patients who have completed previous treatment with three or more kinase inhibitors, including imatinib.

  

• Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes

  Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes.

  

• Quillivant XR (methylphenidate) for Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

  Quillivant XR (methylphenidate) is a psychostimulant drug indicated for Attention Deficit Hyperactivity Disorder (ADHD).

  

• Quizartinib Indicated for the Treatment of FLT3-ITD AML

  Quizartinib is an investigational oral selective FLT3 inhibitor being developed for the treatment of adult patients with acute myeloid leukaemia (AML) having FLT3 internal tandem duplication (ITD) mutation.

  

• QUVIVIQ (daridorexant) for the Treatment of Insomnia, USA

  QUVIVIQ™ (daridorexant) is a new treatment option developed by Idorsia Pharmaceuticals for adult patients with insomnia.

  

R

• RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis

  Afinitor (everolimus), formerly known as RAD001, is a macrolide antibiotic derived from rapamycin that is being investig

  

• Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

  Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

  

• Rapamune (sirolimus) for the Treatment of Lymphangioleiomyomatosis (LAM)

  Rapamune (sirolimus), an immunosuppressive agent, is the first approved medicine in the US for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that affects the lungs, kidneys and the lymphatic system.

  

• Rapiacta (peramivir) – Neuraminidase Inhibitor for Treatment of Influenza

  Rapiacta (peramivir) as is a neuraminidase inhibitor discovered and developed by BioCryst Pharmaceuticals for the treatm

  

• Rasagiline – Second-Generation MAO-B Inhibitor for the Treatment of Parkinson’s Disease

  Azilect® (rasagiline) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease (PD).

  

• Rasilez – Innovative Treatment for Hypertension

  The product of a joint development programme between Swiss companies Speedel and Novartis, Rasilez (aliskiren) is an ora

  

• Ravicti (glycerol phenylbutyrate) for Treatment of Urea Cycle Disorders (UCD)

  Ravicti (glycerol phenylbutyrate) is indicated for the treatment of Urea Cycle Disorders (UCD) in adults and paediatric patients aged two and above.

  

• REBLOZYL for the Treatment of Anaemia Associated with Beta-Thalassemia, US

  REBLOZYL is a first-in-class treatment for patients affected by conditions influenced by anaemia.

  

• REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19

  REGEN-COV™ (casirivimab with imdevimab) is an investigational monoclonal antibody cocktail authorised for the treatment of mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older who are infected with SARS-COV-2 and are at high risk of progression to severe Covid-19.

  

• Relyvrio (sodium phenylbutyrate/taurursodiol) to Treat Amyotrophic Lateral Sclerosis, USA

  Relyvrio is an oral, fixed-dose combination therapy for amyotrophic lateral sclerosis (ALS) in adults.

  

• Rember – Novel Therapy for Alzheimer’s Disease

  Rember (methylthioninium chloride) is a potential disease-modifying therapy for Alzheimer's disease that is under develo

  

• Remdesivir for Potential Treatment of Covid-19

  Remdesivir is an investigational antiviral drug being developed by Gilead Sciences for the treatment of COVID-19, a coronavirus disease, and Ebola virus infection.

  

• Repatha for the Treatment of Heterozygous and Homozygous Familial Hypercholesterolaemia, US

  The FDA approved Repatha in December 2017 to help prevent heart attacks, strokes, and coronary revascularisations.

  

• Restanza

  Restanza (cethromycin) is a second-generation ketolide, once-a-day oral antibiotic that is under review for approval by

  

• Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers

  Retevmo™ (selpercatinib) is the first therapy approved for the treatment of three rearranged during transfection (RET)-driven cancer indications.

  

• Revatio (Sildenafil) – Treatment for Pulmonary Arterial Hypertension

  Revatio is an approved formulation developed by Pfizer for the treatment of pulmonary arterial hypertension. The drug w

  

• Revcovi for the Treatment of ADA-SCID

  Revcovi (elapegademase-lvlr) is a PEGylated recombinant adenosine deaminase (rADA) enzyme indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients.

  

• Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL)

  Revlimid (lenalidomide) oral capsules are indicated for the treatment of Mantle Cell Lymphoma (MCL).

  

• Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia

  Rexulti (brexpiprazole) is a newly-discovered psychotropic compound indicated as an add-on therapy for major depressive disorder (MDD) and as a treatment for schizophrenia.

  

• Rezdiffra for the Treatment of Noncirrhotic Non-alcoholic Steatohepatitis, US

  Rezdiffra is the first FDA-approved medication to treat NASH.

  

• Rezular – Oral Treatment for IBS

  Developed by AGI Therapeutics, Rezular (arverapamil) is an orally administered triple-action intestinal regulator indica

  

• REZUROCK™ (belumosudil) for the Treatment of Chronic Graft-Versus-Host Disease

  REZUROCK™ (belumosudil) is an oral kinase inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 years and older who have received at least two failed previous lines of alternative systemic therapy.

  

• RiaSTAP – Treatment for Congenital Fibrinogen Deficiency (CFD)

  CSL Behring's RiaSTAP is a lyophilised fibrinogen concentrate targeted at the treatment of congenital fibrinogen deficiency (CFD). It can also be used for the treatment of afibrinogenemia and hypofibrinogenemia.

  

• Rifapentine

  Rifapentine is an antibiotic drug developed by Sanofi-aventis for treating tuberculosis (TB). It is marketed under the

  

• Rinvoq (upadacitinib) for the Treatment of Active Crohn’s Disease, USA

  Rinvoq is approved in the US and Europe for active Crohn’s disease.

  

• Rituxan for the Treatment of Non-Hodgkin’s Lymphoma, US

  Rituxan was developed by Biogen Idec, a biotechnology company based in the US, together with the copromotion partner Genentech.

  

• Rixubis (coagulation factor IX (recombinant)) for the Treatment of Haemophilia B

  Rixubis [coagulation factor IX (recombinant)] is indicated for the control and prevention of bleeding episodes and perioperative management in the treatment of adult patients suffering from haemophilia B.

  

• Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours

  Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced solid tumours in adult and paediatric patients.

  

• Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer

  Poly adenosine diphosphate ribose polymerase (PARP) inhibitor Rubraca® (rucaparib) is indicated for the treatment of breast cancer susceptibility gene (BRCA) mutation-linked advanced ovarian cancer.

  

• Ruconest for Treatment of Hereditary Angioedema (HAE)

  Ruconest (C1 Esterase Inhibitor [Recombinant]) is a recombinant approved for treatment of acute angioedema attacks in patients suffering from hereditary angioedema (HAE).

  

• Rukobia (fostemsavir) for the Treatment of HIV

  Rukobia (fostemsavir) is an antiretroviral drug, developed by ViiV Healthcare, for the treatment of HIV-1 infection in adult patients.

  

• Rupintrivir (AG7088)

  Agouron Pharmaceuticals, a subsidiary of Pfizer, has pioneered the development of rupintrivir (AG7088), an experimental treatment for the common cold.

  

• Ruzurgi (amifampridine) for the Treatment of LEMS

  Ruzurgi® (amifampridine) is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in paediatric patients.

  

• Rybelsus (Semaglutide) for the Treatment of Type 2 Diabetes

  Rybelsus® (semaglutide) is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adult patients.

  

• RYBREVANT (amivantamab-vmjw) for the Treatment of Non-Small Cell Lung Cancer

  Rybrevant (amivantamab-vmjw) is the first fully-human bispecific antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has advanced on or after platinum-based chemotherapy.

  

• Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

  Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.

  

• Rylaze™ (asparaginase erwinia chrysanthemi (recombinant) rywn)

  Rylaze (asparaginase erwinia chrysanthemi (recombinant) rywn), formerly known as JZP458, is an asparagine-specific enzyme approved for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in certain adult and paediatric patients.

  

• RYSTIGGO (rozanolixizumab-noli) for the Treatment of Generalised Myasthenia Gravis, USA

  RYSTIGGO® is the first FDA-approved therapy for generalised myasthenia gravis with anti-AChR or anti-MuSK positive antibody.

  

• RYTELO for the Treatment of Myelodysplastic Syndromes, US

  The vial is available in 47mg and 188mg dosage strengths.

  

S

• Sabril (Vigabatrin) – Treatment for Refractory Complex Partial Seizures and IS

  Sabril (vigabatrin) is an antiepileptic drug indicated for the treatment of refractory complex partial seizures (CPS) and infantile spasms (IS). It was developed by Ovation Pharmaceuticals, which was later acquired by Lundbeck.

  

• Saphnelo (Anifrolumab-fnia) for the Treatment of Systemic Lupus Erythematosus

  Saphnelo is the only novel therapy approved for systemic lupus erythematosus (SLE) in more than a decade.

  

• Sarclisa (isatuximab) for the Treatment of Multiple Myeloma, USA

  Sarclisa® is the first approved anti-CD38 therapy along with standard-of-care treatment to treat newly diagnosed multiple myeloma.

  

• Sativex (Nabiximols) for the Treatment of Multiple Sclerosis, Europe

  Sativex®, also known as Nabiximols, is indicated to treat spasticity due to multiple sclerosis and cancer pain.

  

• Saxagliptin – Treatment for Type 2 Diabetes

  The product of a joint development programme between AstraZeneca and Bristol-Myers Squibb, saxagliptin is a member of a

  

• Saxenda (liraglutide) for the Treatment of Obesity, US

  Saxenda is a GLP-1 receptor agonist to treat obesity in adolescents with a 60kg body weight and an initial BMI of 30kg/m².

  

• Scemblix (asciminib) for the Treatment of Chronic Myeloid Leukaemia

  Scemblix (asciminib) is a first-in-class STAMP inhibitor indicated for treating chronic myeloid leukaemia (CML) in adult patients.

  

• Secuado (asenapine) for the Treatment of Schizophrenia

  Secuado® (asenapine) is an atypical anti-psychotic drug approved for the treatment of schizophrenia in adult patients. It is the first drug approved as transdermal patch formulation for schizophrenia treatment in the US.

  

• Selincro (nalmefene) – Treatment for Alcohol Dependence

  Selincro (nalmefene) is an injected drug for the treatment of alcohol dependence.

  

• Semagacestat – Gamma Secretase Inhibitor for Alzheimer’s Disease

  Semagacestat (LY-450139) was a gamma secretase inhibitor being developed as a treatment for Alzheimer's disease by Eli

  

• Seroquel – Treatment for Major Depressive Disorder (MDD)

  Seroquel (quetiapine fumarate) is an anti-psychotic drug indicated as an add-on treatment for patients suffering from

  

• SF1126 –

  SF1126 is indicated for treating chronic lymphocytic leukaemia (CLL). The drug is being developed by US-based Semafore

  

• Shingrix (herpes zoster subunit vaccine) for the Prevention of Shingles

  Shingrix is a recombinant subunit shingles vaccine that was discovered and developed by GlaxoSmithKline (GSK).

  

• Signifor (Pasireotide) – Treatment for Cushing’s Disease

  Signifor (SOM230 / Pasireotide) is a somatostatin analogue indicated for the treatment of patients with Cushing's disease for whom surgery has failed. The drug is developed and manufactured by Novartis.

  

• Siklos (hydroxyurea) for the Treatment of Children with Sickle Cell Anaemia

  Siklos® is an orally administered tablet form of hydroxyurea that is indicated for the treatment of sickle-cell anaemia in paediatric patients aged two years and older.

  

• Silenor (doxepin) for the Treatment of Insomnia

  Silenor (doxepin) is a tricyclic antidepressant indicated for the treatment of insomnia. It was developed by Somaxon Pharmaceuticals.
  In March 2010, the US Food and Drug Administration (FDA) approved Silenor for the treatment of insomnia characterised by difficulty with sleep maintenance.

  

• Simbrinza (brinzolamide/brimonidine tartrate) for the Reduction of Elevated Intraocular Pressure

  Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of Novartis.

  

• Simponi (Golimumab) – Treatment for Ulcerative Colitis (UC)

  Simponi (golimumab) is a subcutaneous injection for the treatment of adult patients living with ulcerative colitis (UC). The drug was discovered and developed by Janssen Biotech.

  

• SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)

  SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody.

  

• Sirturo (bedaquiline) for Treatment of Pulmonary Multi-Drug Resistant Tuberculosis (TB)

  Sirturo (bedaquiline) was developed by Janssen Therapeutics, a division of Janssen Products. It is indicated for the treatment of multi-drug resistant tuberculosis (MDR-TB).

  

• Sitavig (Acyclovir) – Treatment for Herpes Labialis

  Sitavig (acyclovir) is a muco-adhesive buccal tablet indicated for the treatment of recurring Herpes Labialis. The drug is manufactured and marketed by BioAlliance Pharma.

  

• Sivextro for Treatment of Acute Bacterial Skin and Skin Structure Infections

  Sivextro (tedizolid phosphate) is an oxazolidinone class antibacterial drug indicated for treatment of adult patients infected with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

  

• Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis, USA

  Skyrizi® is an interleukin-23 inhibitor indicated to treat plaque psoriasis, active psoriatic arthritis and Crohn’s disease.

  

• Sohonos (palovarotene) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP), USA

  Sohonos, developed by Ipsen, is the first and only approved treatment for patients with fibrodysplasia ossificans progressiva.

  

• Soliqua 100/33 for the Treatment of Type 2 Diabetes

  Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes.

  

• Soliris (Eculizumab) for the Treatment of Generalised Myasthenia Gravis (gMG), USA

  Soliris® (eculizumab) is the first targeted therapy approved for paediatric patients with gMG in Europe.

  

• Solithera (solithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia

  Solithera (solithromycin) is a next-generation macrolide antibiotic developed by Cempra as a treatment for community-acquired bacterial pneumonia.

  

• Solosec (secnidazole) for the Treatment of Bacterial Vaginosis and Trichomoniasis

  Solosec® (secnidazole) is a next-generation antibiotic indicated for the treatment of bacterial vaginosis and trichomoniasis.

  

• Sotagliflozin for the Treatment of Heart Failure, US

  Sotagliflozin is a once-daily oral drug indicated to reduce the risk of cardiovascular death in adults.
  

  

• Sotyktu (deucravacitinib) to Treat Moderate to Severe Plaque Psoriasis, USA

  Sotyktu (deucravacitinib) is the first oral TYK2 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis.

  

• Sovaldi (sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

  Sovaldi (sofosbuvir), developed by Gilead Sciences (Gilead), is an oral nucleotide analog inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection.

  

• Spevigo (Spesolimab-sbzo) to Treat Generalised Pustular Psoriasis Flares, USA

  Spevigo (spesolimab-sbzo) is the first approved treatment for generalised pustular psoriasis flares in adults.

  

• SPINRAZA for the Treatment of Spinal Muscular Atrophy, US

  SPINRAZA is available as a clear, colourless solution of 12mg/5ml dosage strength.

  

• Spiriva – Treatment for Chronic Obstructive Pulmonary Disease

  Spiriva is an anticholinergic drug targeted at chronic obstructive pulmonary disease (COPD). It contains tiotropium bromide as the active ingredient.

  

• Spritam (levetiracetam) for the Treatment of Epilepsy

  Spritam (levetiracetam) is an adjunctive therapy indicated for the treatment of seizures in patients with epilepsy, the fourth most common neurological disorder affecting people of all age groups.

  

• Steglatro (ertugliflozin) for the Treatment of Type 2 Diabetes

  Steglatro™ (ertugliflozin) is a combination drug indicated for the improvement of glycaemic control in adult patients with Type 2 diabetes mellitus.

  

• Stelara for the Treatment of Moderate to Severe Crohn’s Disease, US

  Stelara was approved for the treatment of US adult patients with moderately to severely active UC in 2019 by the FDA.

  

• Stimufend (pegfilgrastim-fpgk) for the Treatment of Febrile Neutropenia, USA

  Stimufend® (pegfilgrastim-fpgk) is a biosimilar to Neulasta® for use in patients at risk for febrile neutropenia.
  

  

• Stimuvax – Investigational Therapeutic Cancer Vaccine

  Stimuvax, formerly known as BLP25 liposome vaccine (L-BLP25), is an investigational therapeutic vaccine being developed to provide immunity against the cancer cells that over express Mucin 1 (MUC-1), a glycoprotein antigen

  

• Stiolto Respimat for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

  Stiolto Respimat (tiotropium bromide and olodaterol), an oral inhalation spray indicated for the treatment of chronic obstructive pulmonary disease (COPD), is manufactured by Boehringer Ingelheim Pharmaceuticals, the US subsidiary of Boehringer Ingelheim Corp.

  

• Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC)

  Stivarga (Regorafenib) is an oral multikinase inhibitor developed by Bayer HealthCare for the treatment of metastatic colorectal cancer (mCRC).

  

• Strensiq (asfotase alfa) for the Treatment of Hypophosphatasia

  Strensiq (asfotase alfa) is the first enzyme replacement therapy (ERT) approved in the US for the treatment of perinatal / infantile and juvenile-onset hypophosphatasia (HPP), which is a life-threatening and ultra-rare metabolic disorder.

  

• Stribild – A Single Tablet Regimen for the Treatment of HIV-1

  Stribild is a combination of four compounds; elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The drug is indicated for the treatment of HIV-1 infection in adults who have never received antiretroviral treatment for the disease.

  

• Striverdi Respimat for the Maintenance Treatment of COPD

  Striverdi Respimat (olodaterol) is an inhalation spray indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema.

  

• Sublocade™ for the Treatment of Opioid Use Disorder

  Sublocade™ (buprenorphine extended-release) is a partial agonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in adults.

  

• SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease

  SUN-101 (Glycopyrrolate) is an inhalation solution developed by Sunovion Pharmaceuticals as a treatment for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

  

• Sunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, USA

  Sunlenca (lenacapavir) is a first-in-class, long-acting HIV capsid inhibitor approved for the treatment of HIV-1 infection.

  

• Surfaxin (Lucinactant) – Treatment for Preventing Infant RDS

  Surfaxin (Lucinactant) is a non-pyrogenic pulmonary surfactant used for the prevention of respiratory distress syndrome (RDS) in premature infants.

  

• Sustiva (Efavirenz) – Treatment for HIV-1 Infected Paediatric Patients

  Sustiva (efavirenz) is an antiretroviral indicated for the treatment of paediatric patients with the HIV-1 infection.

  

• Susvimo (ranibizumab) for Treating Wet Age‑related Macular Degeneration

  Susvimo™ (ranibizumab) is a VEGF inhibitor indicated for the treatment of neovascular age-related macular degeneration (nAMD).

  

• Sutent (Sunitinib Malate) – Treatment for Pancreatic Neuroendocrine Tumours

  Sutent (sunitinib malate) is an oral multikinase inhibitor which is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumours (NET).

  

• Sycrest (asenapine) – Treatment for Bipolar I Disorder

  Sycrest (asenapine) is an antipsychotic medicine indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder. The drug was developed by Merck.

  

• Syfovre (pegcetacoplan) for the Treatment of Geographic Atrophy, USA

  Syfovre™ is the first FDA-approved treatment for geographic atrophy, an advanced form of age-related macular degeneration.

  

• Sylvant (siltuximab) for the Treatment of Multicentric Castleman’s Disease

  Sylvant (siltuximab) is indicated for the treatment of patients with multi-centric Castleman’s disease (MCD) in the US.

  

• Symbicort (budesonide and formoterol) for the Treatment of Asthma

  Symbicort is a combination drug comprising an inhaled corticosteroid and a long-acting bronchodilator to treat asthma.

  

• Symdeko (tezacaftor/ivacaftor and ivacaftor) for the Treatment of Cystic Fibrosis

  Symdeko™ (tezacaftor/ivacaftor and ivacaftor) is a combination drug indicated for the treatment  of cystic fibrosis (CF) in people aged 12 years and above.

  

• Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia

  Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for the treatment of patients with chronic myelogenous leukaemia (CML) in both chronic and accelerated phases.

  

T

• T-705 – Antiviral Drug for Influenza by Toyama Chemical of Japan

  T-705 is a novel oral agent indicated for the treatment of influenza that is under development by Toyama Chemical of Jap

  

• Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

  Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that results in mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping.

  

• Tafinlar (Dabrafenib) – Treatment for Metastatic Melanoma

  Tafinlar (dabrafenib) is a single-agent oral treatment indicated for the treatment of unresectable or metastatic melanoma in adult patients.

  

• Tagrisso (osimertinib) For the Treatment of EGFR mutation in Non-Small Cell Lung Cancer

  Tagrisso (osimertinib) is a once-daily tablet developed by AstraZeneca for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation associated with non-small cell lung cancer (NSCLC).

  

• Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema

  Takhzyro (lanadelumab-flyo) is indicated for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older.

  

• Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

  Taltz® (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs.

  

• TALVEY for the Treatment of Multiple Myeloma, US

  The US FDA granted accelerated approval to TALVEY in August 2023.
  

  

• Talzenna (talazoparib) for the Treatment of Advanced Breast Cancer

  Talzenna™ (talazoparib) is an inhibitor of the poly adenosine diphosphate (ADP) ribose polymerase (PARP) enzyme that is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) negative breast cancer in adult patients with the BRCA-mutated (gBRCAm) gene.

  

• Tamiflu – Oral Anti-Viral Treatment Agent

  Tamiflu or oseltamivir is a prescription drug used for prophylaxis and treatment of flu caused by influenza virus types A (H1N1) and B.

  

• Tanzeum (albiglutide) for Treatment of Type 2 Diabetes

  Tanzeum (albiglutide), developed by GlaxoSmithKline (GSK), is a GLP-1 receptor agonist indicated for treatment of type 2 diabetes.

  

• Taranabant CB1 Receptor Inverse Agonist for Management of Obe

  Taranabant is a highly selective cannabinoid-1 (CB1) receptor inverse agonist developed by Merck & Co for the treatment

  

• Tarceva Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer

  Tarceva (erlotinib) is an oral anti-cancer drug developed by OSI Pharmaceuticals, Genentech and Roche. It is a member of

  

• TARPEYO for the Treatment of IgAN, US

  TARPEYO is the first and only FDA-approved therapy to reduce the loss of kidney function in adults with primary IgAN.
  

  

• Tasigna (Nilotinib)

  Tasigna (nilotinib) is indicated for treating Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML). Th

  

• TAVALISSE (fostamatinib disodium hexahydrate) for the Treatment of Chronic Immune Thrombocytopenia

  TAVALISSE™ is a twice-daily regimen indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment.

  

• Tavneos (avacopan) for the Treatment of ANCA-Associated Vasculitis

  Tavneos (avacopan) is the first FDA-approved oral selective complement 5a receptor inhibitor drug for ANCA-associated vasculitis.

  

• Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma

  Tazverik is the first approved treatment for metastatic/locally advanced epithelioid sarcoma in patients aged 16 years and older.

  

• TB402 – Treatment of VTE and AF

  The product of a co-development programme between ThromboGenics, a Belgian biotechnology company, and BioInvent Internat

  

• TBRIA (calcitonin-salmon) for the Treatment of Postmenopausal Osteoporosis

  TBRIA (calcitonin-salmon [rDNA origin] delayed release tablet) is the first oral recombinant salmon calcitonin, developed by Tarsa Therapeutics, for the treatment of postmenopausal osteoporosis.

  

• Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL)

  Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) chimeric antigen receptor (CAR) T-cell therapy is the first and only approved cell-based gene therapy for the treatment of mantle cell lymphoma (MCL).

  

• TECELRA (afamitresgene autoleucel) for the Treatment of Synovial Sarcoma, USA

  TECELRA® (afamitresgene autoleucel) is the first novel treatment option for individuals with synovial sarcoma in more than ten years.

  

• Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

  Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1.

  

• Tecfidera (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS)

  Tecfidera (BG-12/Dimethyl Fumarate) is a first-line oral treatment indicated for patients with relapsing-remitting multiple sclerosis (RRMS). The drug was developed by Biogen Idec.

  

• Technivie (Ombitasvir, Paritaprevir, Ritonavir) for the Treatment of Genotype 4 Chronic Hepatitis C

  Technivie (ombitasvir, paritaprevir and ritonavir) is the first direct-acting antiviral drug approved for the treatment of genotype 4 (GT4) chronic hepatitis C virus (HCV) infection in the US.

  

• Tegsedi for the Treatment of Polyneuropathy of hATTR Amyloidosis

  Tegsedi™ (inotersen) is an anti-sense oligonucleotide indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients.

  

• Telbivudine – Investigational Drug

  The product of a joint collaborative programme between Idenix Pharmaceuticals and Novartis Pharma, telbivudine (oral L-d

  

• Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer

  Tepmetko (tepotinib) is an oral kinase inhibitor approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). It is the first and only US Food and Drug Administration (FDA) approved mesenchymal-epithelial transition (MET) inhibitor with once-daily oral dosing.

  

• Terlivaz (terlipressin) for the Treatment of Hepatorenal Syndrome (HRS), USA

  Terlivaz (terlipressin) is the first and only approved treatment of hepatorenal syndrome (HRS) in adults.

  

• Tesmilifene – Chemopotentiator for Cancer

  Tesmilifene is a small molecule chemopotentiator under development by YM BioSciences, a Candian pharmaceutical company t

  

• Tesofensine Anti-Obesity Medication

  Under development by NeuroSearch, a Danish pharmaceutical company, tesofensine is a novel treatment for obesity. A serot

  

• Tezspire (tezepelumab-ekko) for the Treatment of Severe Asthma, USA

  Tezspire (tezepelumab-ekko) is the first and only biologic indicated as an add-on maintenance treatment for severe asthma.

  

• TIBSOVO (ivosidenib) for Treating Relapsed or Refractory AML and Advanced Cholangiocarcinoma, US

  TIBSOVO® (ivosidenib) is the first approved targeted therapy for patients with IDH1-mutated advanced cholangiocarcinoma.

  

• TIGLUTIK (Riluzole) for the Treatment of Amyotrophic Lateral Sclerosis

  TIGLUTIK (Riluzole) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

  

• Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer

  Tivdak (tisotumab vedotin-tftv) is the first and only approved antibody-drug conjugate to treat adults with cervical cancer.

  

• Tivicay (Dolutegravir) for the Treatment of HIV-1 Infection

  Tivicay (dolutegravir) is an integrase inhibitor indicated for the treatment of the HIV-1 infection in adults and children aged 12 years and above.

  

• Tivorbex (indomethacin) for the Treatment of Acute Pain

  Tivorbex (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults.

  

• Toujeo for the Treatment of Type 1 and Type 2 Diabetes

  Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients.

  

• TRA-SCH-530348

  TRA-SCH 530348 is an oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of ath

  

• Tradjenta Indicated for the Treatment of Type II Diabetes

  Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.

  

• Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

  Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

  

• Trastuzumab –

  Trastuzumab, indicated for the treatment of recurrent gastric cancer with a high concentration of HER2 (human epiderma

  

• Tremfya (guselkumab) for the Treatment of Plaque Psoriasis

  Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in adults.

  

• Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes, USA

  Novo Nordisk’s Tresiba® (insulin degludec) is indicated for the treatment of Type 1 and Type 2 diabetes.

  

• Tretten for the Treatment of Congenital Factor XIII Deficiency

  Tretten is the world’s first recombinant treatment available for the prevention of bleeding in adults and children suffering from congenital factor XIII (FXIII) A-subunit deficiency.

  

• Treximet – Next-Generation Treatment for Migraine

  The product of a joint development programme between US drug development company Pozen and GSK, Treximet is a novel comb

• TRIKAFTA (elexacaftor, ivacaftor and tezacaftor) for the Treatment of Cystic Fibrosis

  TRIKAFTA is the first triple combination therapy containing elexacaftor, ivacaftor, and tezacaftor indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above and having a F508del mutation and one minimal function mutation.

  

• Triumeq (dolutegravir/abacavir/lamivudine) for the Treatment of HIV

  Triumeq (dolutegravir/abacavir/lamivudine) is an investigational drug indicated for the treatment of adult and adolescent patients (minimum age of 12 years and with a minimum weight of 40kg) affected with Human Immunodeficiency Virus (HIV).

  

• Trobalt / Potiga – Treatment for Partial-Onset Seizure

  Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old.

  

• Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer

  Gilead’s Trodelvy is indicated for the treatment of locally advanced or metastatic breast cancer and urothelial cancer.

  

• Trofinetide for the Treatment of Rett Syndrome, US

  Daybue is the first and only drug approved for the treatment of Rett syndrome, a rare neurodevelopmental disorder.

  

• Trogarzo (ibalizumab-uiyk) for the Treatment of Multidrug-Resistant HIV-1 Infection

  Trogarzo™ is indicated for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced patients.

  

• Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)

  Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).

  

• Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes

  Trulicity (dulaglutide) is a glucagon-like peptide 1 receptor agonist (GLP-1 agonist) indicated for the treatment of adults with type 2 diabetes. The drug was discovered and developed by Eli Lilly and Company.

  

• Trumenba Vaccine for Prevention of Meningococcal Meningitis B Disease

  Trumenba is a vaccine licenced in the US for the prevention of invasive meningococcal meningitis B in adolescents and young adults between ten and 25 years.

  

• TRUQAP (capivasertib) for the Treatment of Breast Cancer, USA

  TRUQAP™ (capivasertib) in combination with Faslodex® (fulvestrant) is indicated for the treatment of breast cancer in adults.

  

• TRUSELTIQ™ (infigratinib) for the Treatment of Cholangiocarcinoma

  TRUSELTIQ™ (infigratinib) is an oral kinase inhibitor indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor II (FGFR2) fusion in adult patients.

  

• Truvada – Antiretroviral Treatment to Prevent HIV

  Truvada (emtricitabine and tenofovir disoproxil fumarate) is an antiretroviral indicated for preventing or reducing the risk of acquiring HIV-1.

  

• Truxima (rituximab) for the Treatment of Cancer

  ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.

  

• Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for Long-term Treatment of COPD

  Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic drug indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It was developed by Forest Laboratories in collaboration with Spanish company Almirall.

  

• TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer

  TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.

  

• Tygacil – Broad-Spectrum Antibiotic for Empiric

  Developed by Wyeth Pharmaceuticals, Tygacil (tigecycline) is the first in a new class of antibiotics, the glycylcyclines

• Tykerb – Dual Tyrosine Kinase Inhibitor

  Tykerb (lapatinib ditosylate) is an epidermal growth factor receptor (EGFR) and ErbB-2 (Her2/neu) dual tyrosine kinase i

  

• Tyrvaya (varenicline) for the Treatment of Dry Eye Disease

  Tyrvaya (varenicline) is the first and only nasal spray approved by the FDA for the treatment of dry eye disease.

  

• Tysabri – Therapeutic Monoclonal Antibody (Mab) for the Treatment of Multiple Sclerosis

  The product of a joint development programme between by Elan Pharmaceuticals and Biogen, Tysabri (natalizumab) is a huma

  

U

• Uceris (Budesonide) for Treating Ulcerative Colitis

  Uceris (budesonide) is glucocorticoid receptor that is indicated for the treatment of ulcerative colitis. It is developed by US-based biopharmaceutical company Santarus, in collaboration with Cosmo Technologies.

  

• UKONIQ™ (umbralisib) for the Treatment of Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)

  UKONIQ™ (umbralisib) is the first and only oral, dual inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, indicated for the treatment of previously treated relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL) in adult patients.

  

• Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria

  Ultomiris™ (ravulizumab-cwvz) is a complement inhibitor drug approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.

  

• Ultresa – Treatment for Exocrine Pancreatic Insufficiency (EPI)

  Aptalis Pharma's Ultresa is indicated for the treatment of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis or other conditions. It was approved by the US Food and Drug Administration.

  

• Ustekinumab, Treatment for Plaque Psoriasis by Centocor and Janssen-Cilag

  Ustekinumab (CNTO 1275), a human anti-interleukin 12 (IL-12) and anti-interleukin 23 (IL-23) monoclonal antibody (MAb),

  

V

• V1512 (melevodopa/carbidopa) for the Treatment of Parkinson’s Disease, Italy

  V1512 (melevodopa/carbidopa) is an effervescent tablet formulation for the treatment of Parkinson's disease.

  

• Vabysmo (faricimab-svoa) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema

  Vabysmo™ (faricimab-svoa) is the first injectable eye medicine approved for two conditions, nAMD and DME, simultaneously.

  

• Valtorcitabine – Combination Drug Therapy for Chronic Hepatitis B

  In partnership with Novartis Pharma, Idenix Pharmaceuticals is developing valtorcitabine (L-deoxycytidine) as part of a

  

• VANFLYTA (quizartinib) for the Treatment of Acute Myeloid Leukaemia, USA

  VANFLYTA® (quizartinib) is the first and only FLT3 inhibitor indicated to treat newly diagnosed acute myeloid leukaemia.

  

• Varithena (Polidocanol Injectable Foam) for the Treatment of Varicose Veins

  Varithena (Polidocanol Injectable Foam) is injectable foam indicated for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.

  

• VariZIG (Varicella Zoster Immune Globulin Human) for the Treatment of Chickenpox

  VariZIG (Varicella Zoster Immune Globulin Human) is an antibody drug that is indicated for the post-exposure prevention of chickenpox in immunocompromised children, newborns and pregnant women. It was developed by Cangene Corporation, a Canada-based company.

  

• Veletri (epoprostenol) for the Treatment of Pulmonary Arterial Hypertension (PAH)

  Veletri (epoprostenol) is an eicosanoid indicated for controlling functions in the body such as blood pressure and muscle contractions. It was originally developed by GeneraMedix.

  

• Velphoro for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis

  Velphoro (sucroferric oxyhydroxide / PA21) is an iron-based Ca-free phosphate binder for treating Hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis.

  

• Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

  Developed by Gilead Sciences, Vemlidy (tenofovir alafenamide) is indicated for treatment of hepatitis B (HBV) virus infection with compensated liver disease in adult patients.

  

• Venclexta (Venetoclax) for the Treatment of Chronic Lymphocytic Leukaemia

  Venclexta (Venetoclax) is an oral formulation developed by AbbVie in collaboration with Genentech and Roche, for the treatment of chronic lymphocytic leukaemia patients with 17p deletion.

  

• Veopoz for the Treatment of Chaple Disease, US

  Veopoz received FDA approval for the treatment of PLE in August 2023.

  

• VEOZAH (fezolinetant) to Treat Vasomotor Symptoms Due to Menopause, USA

  VEOZAH™ (fezolinetant) is an FDA-approved nonhormonal treatment for vasomotor symptoms (VMS) due to menopause.
  

  

• VERQUVO (vericiguat) for the Treatment of Heart Failure with Reduced Ejection Fraction, USA

  Verquvo (vericiguat) is the first soluble guanylate cyclase (sGC) stimulator approved to treat heart failure.

  

• Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer

  Verzenio (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

  

• Vesicare – Oral Selective Muscarinic Receptor

  Vesicare (solifenacin succinate) is an oral selective muscarinic receptor antagonist developed by Yamanouchi, Japan's th

  

• Viberzi (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D)

  Viberzi (eluxadoline), an oral tablet developed by Actavis, is indicated for the treatment of adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).

  

• Viekirax and Exviera for the Treatment of Chronic Hepatitis C Virus Infection

  Viekirax (ombitasvir / paritaprevir / ritonavir) and Exviera (dasabuvir) is indicated for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection and compensated cirrhosis.

  

• Viibryd – Treatment for Major Depressive Disorder

  Viibryd (Vilazodone) is an antidepressant manufactured for the treatment of adults with major depressive disorder (MDD). T

  

• Vildagliptin Oral Antidiabetic Agent – For The Treatment of Type 2 Diabetes

  Novartis' Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV

• VILTEPSO (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)

  VILTEPSO™ (viltolarsen) is an antisense oligonucleotide drug indicated to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder, in patients with a confirmed DMD gene mutation that is vulnerable to exon 53 skipping therapy.

  

• Vimizim (elosulfase alfa) for Treating Morquio A Syndrome

  Vimizim (elosulfase alfa / BMN 110) is an enzyme replacement therapy (ERT) for treating patients with Morquio A syndrome (MPS IVA).

  

• VIMPAT (lacosamide) for the Treatment of Primary Generalised Tonic-Clonic Seizures (PGTCS)

  VIMPAT® (lacosamide) is a federally-controlled drug (CV) indicated as a supplementary therapy for the treatment of primary generalised tonic-clonic seizures (PGTCS) in patients aged four years and older.

  

• Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion

  Vitrakvi® (larotrectinib) is an oral tyrosine kinase (TRK) inhibitor indicated for the treatment of advanced solid tumours in adult and paediatric patients with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

  

• VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA

  VIVJOA is the first and only FDA-approved drug for the treatment of recurrent vulvovaginal candidiasis (RVVC) in females.

  

• Vizimpro (dacomitinib) for the Treatment of Non-Small Cell Lung Cancer

  Vizimpro® (dacomitinib) is a kinase inhibitor indicated for the treatment of EGFR-positive advanced non-small cell lung cancer (NSCLC) patients diagnosed with exon 19 deletion or exon 21 L858R substitution mutations.

  

• Volasertib for Treatment of Acute Myeloid Leukaemia (AML)

  Volasertib (BI 6727) is a selective and potent polo-like kinase (Plk) inhibitor currently being investigated for the treatment of patients with acute myeloid leukaemia (AML).

  

• VONJO (pacritinib) to Treat Myelofibrosis, USA

  VONJO (pacritinib) is the first oral kinase inhibitor approved for the treatment of myelofibrosis and thrombocytopaenia.

  

• VOQUEZNA (vonoprazan) for the Treatment of Helicobacter Pylori Infection, USA

  VOQUEZNA is a co-packaged medicine containing vonoprazan with antibiotics for the treatment of H pylori infection.

  

• VORANIGO (vorasidenib) for the Treatment of Grade 2 IDH-mutant Glioma, USA

  VORANIGO® (vorasidenib) is the first FDA-approved targeted therapy for Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma.

  

• Voraxaze (glucarpidase) for the Treatment of Toxic Plasma Methotrexate Concentrations

  Voraxaze (glucarpidase) is an antidote indicated for the treatment of plasma methotrexate (MTX) toxicity in patients with delayed elimination of methotrexate due to kidney dysfunction.

  

• Voreloxin, Anti-Cancer Quinolone Derivative

  Voreloxin is a quinolone derivative being investigated for the treatment of various cancers. The drug is being develop

  

• Vosaroxin – Treatment for Myeloid Leukaemia

  Vosaroxin is a first-in-class anticancer quinolone derivative (AQD) under development by Sunesis Pharmaceuticals for th

  

• Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

  Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

  

• Votrient – Treatment for Renal Cell Cancer and Soft Tissue Sarcoma

  GlaxoSmithKline's (GSK's) Votrient drug is an approved medication for the treatment of renal cell cancer (RCC). The RRC treatment drug has conditional marketing authorisation in the European Union (EU).

  

• VOWST (faecal microbiota spores, live-brpk) for the Prevention of Recurrent Clostridioides difficile Infection, USA

  VOWST™ is the first and only FDA-approved orally administered microbiota-based therapy to prevent the recurrence of CDI.

  

• VOXZOGO (vosoritide) for the Treatment of Achondroplasia and Open Epiphyses, USA

  VOXZOGO (vosoritide) is the first approved therapeutic treatment for achondroplasia and epiphyses.

  

• Vraylar (cariprazine) for the Treatment of Bipolar Disorder and Schizophrenia

  Designed for specific mood disorders, Vraylar (cariprazine) is approved for bipolar disorder, schizophrenia and major depressive disorder.

  

• Vtama (tapinarof) for the Treatment of Plaque Psoriasis

  Vtama® (tapinarof) is a steroid-free, topical treatment option for mild to severe plaque psoriasis in adults.

  

• Vuity (pilocarpine HCI) for the Treatment of Presbyopia, USA

  Vuity (pilocarpine HCl) eye drop is the first-of-its-kind FDA-approved treatment for age-related blurry presbyopia in adults.

  

• VUMERITY (diroximel fumarate) for the Treatment of Multiple Sclerosis

  VUMERITY™ (diroximel fumarate), previously known as ALKS 8700, is a novel oral formulation indicated for the treatment of relapsing forms of multiple sclerosis (MS).

  

• VYLOY (zolbetuximab) for the Treatment of Gastric Cancer, Japan

  VYLOY™ (zolbetuximab) is the first and only CLDN18.2-targeted therapy approved for the treatment of gastric cancer.
  

  

• Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy

  Vyndaqel (tafamidis meglumine) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).

  

• Vyvanse® (lisdexamfetamine) for the Treatment of Binge-Eating Disorder

  Vyvanse® (lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant indicated for the treatment of moderate-to-severe binge-eating disorder and attention deficit hyperactivity disorder (ADHD).

  

• VYVGART (efgartigimod alfa fcab) for the Treatment of Generalised Myasthenia Gravis, USA

  Developed by argenx, VYVGART is approved in the US, Europe, Japan, China and Israel.

  

W

• WAINUA (eplontersen) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis, USA

  WAINUA™ (eplontersen) is the only medicine for managing transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), allowing self-administration through an auto-injector.

  

• WAKIX (pitolisant) for the Treatment of Cataplexy with Narcolepsy

  WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

  

• Wegovy for the Treatment of Chronic Weight Management, US

  The FDA approved semaglutide under the brand name Wegovy for chronic weight management in adults in June 2021.

  

• Wilate, von Willebrand Factor/Coagulation Factor Concentrate

  Wilate is a von Willebrand Factor/Coagulation Factor VIII (vWF/FVIII) concentrate developed for the treatment of von W

  

• Winrevair (Sotatercept) for the Treatment of Pulmonary Arterial Hypertension, USA

  Winrevair (sotatercept) is a breakthrough biologic treatment for the rare and progressive pulmonary arterial hypertension (PAH).
  

  

X

• Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)

  Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease.

  

• Xalkori – Treatment for Non-Small Cell Lung Cancer

  The FDA approved Xalkori for the treatment of metastatic Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer in August 2011.

  

• Xarelto: Investigational Agent for Treatment and Prevention of Thromboembolic Events

  The product of a joint development programme between Bayer and Johnson & Johnson, Xarelto (rivaroxaban) is a new oral anticoagulant. It is indicated for the primary prevention and treatment of venous thromboembolism (VTE) following orthopaedic surgery. Clinical trials are also ongoing to evaluate Xarelto (rivaroxaban) for stroke prevention in patients with atrial fibrillation and acute coronary syndrome.

  

• Xeljanz (tofacitinib) – Treatment for Rheumatoid Arthritis

  Xeljanz (tofacitinib) is a janus kinase (JAK) 3 inhibitor developed by Pfizer as a treatment for the symptoms of rheumatoid arthritis.

  

• Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis

  Xeljanz XR (tofacitinib citrate) is an 11mg once-daily oral JAK inhibitor developed by Pfizer for the treatment of moderate to severe Rheumatoid Arthritis (RA).

  

• Xeloda – Treatment for Metastatic Colorectal Cancer

  Xeloda is an approved oral drug developed by F. Hoffmann-La Roche (Roche) for treating metastatic colorectal cancer and

  

• Xenpozyme (olipudase alfa) to Treat Acid Sphingomyelinase Deficiency (ASMD), Europe

  Xenpozyme is the first enzyme replacement therapy for acid sphingomyelinase deficiency approved in Japan and Europe.

  

• Xgeva (Denosumab) for the Prevention of Metastatic Bone Cancer

  Xgeva (denosumab) is a preventive medicine developed by Amgen to check the spread of cancer to the bones.

  

• Xhance™ (fluticasone propionate) for the Treatment of Nasal Polyps

  Xhance™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older.

  

• Xiaflex for Treatment of Dupuytren’s Contracture / Peyronie’s Disease

  Xiaflex is the first drug indicated for treating Dupuytren's contracture. The drug was developed by Auxilium Pharmaceuticals in collaboration with BioSpecifics Technologies.

  

• Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease

  Xiidra lifitegrast ophthalmic solution is a twice-a-day eye drop solution developed by Shire as a treatment for the signs and symptoms of dry eye disease in adults.

  

• Xipere (triamcinolone acetonide) for the Treatment of Macular Oedema Associated with Uveitis

  Xipere™ is the first and only FDA-approved therapy for suprachoroidal use to treat macular oedema associated with uveitis.

  

• XL184

  XL184 (cabozantinib) is an indicator to inhibit tumour growth, angiogenesis and metastasis.

  

• Xofigo (Radium 223 dichloride) for the Treatment of Prostate Cancer with Bone Metastases

  Xofigo (radium 223 dichloride) is an intravenous radiotherapeutic drug indicated for the treatment of patients suffering from prostate cancer with bone metastases.

  

• Xolair – Biological Therapy

  The product of a joint development programme between Tanox, Genentech and Novartis, Xolair (omalizumab) is a recombinant

  

• XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, USA

  XOLREMDI™ (mavorixafor) is the first approved therapy specifically indicated to treat patients with WHIM syndrome.

  

• Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation

  Xospata® (gilteritinib) is a feline McDonough sarcoma (FMS) like tyrosine kinase 3 (FLT3) inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutation in adult patients.

• XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  XPOVIO® (selinexor) is the only single-agent oral therapy indicated for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).

  

• Xtandi (enzalutamide) for Treatment of Metastatic Castration-Resistant Prostate Cancer

  Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

  

• Xultophy 100/3.6 for the Treatment of Type 2 Diabetes

  Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes.

  

• XYWAV (calcium, magnesium, potassium, and sodium oxybates) for the Treatment of Cataplexy and Narcolepsy, USA

  Jazz Pharmaceuticals’ XYWAV™ (calcium, magnesium, potassium, and sodium oxybates) is the first US Food and Drug Administration (FDA) approved medicine indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy in over 15 years.

  

Y

• Yervoy (Ipilimumab) – Therapy for Treatment of Metastatic Melanoma

  Yervoy is a monoclonal antibody drug indicated for treating metastatic melanoma. The drug was developed by Bristol-Myers

  

• Yescarta (axicabtagene ciloleucel) for the Treatment of Large B-Cell Lymphoma

  Yescarta™ (axicabtagene ciloleucel) is one of the first chimeric antigen receptor T cell (CAR T) therapies indicated for the treatment of relapsed / refractory large B-cell lymphoma in adult patients.

  

• Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease

  Yupelri™ (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated as a maintenance treatment for chronic obtrusive pulmonary disease (COPD) in adult patients.

  

Z

• Zactima – Tyrosine Kinase Inhibitor

  Zactima (vandetanib) is an orally available tyrosine kinase inhibitor (TKI) developed by AstraZeneca for the treatment o

  

• Zaltrap (ziv-aflibercept) for the Treatment of Metastatic Colorectal Cancer

  Zaltrap (ziv-aflibercept) is a recombinant fusion protein indicated for the treatment of metastatic colorectal cancer (mCRC). It was developed by Sanofi-Aventis in collaboration with Regeneron Pharmaceuticals.

  

• Zegerid – Proton Pump Inhibitor for Treatment of Heartburn

  Zegerid is a proton pump inhibitor (PPI) comprising omeprazole, a leading prescription acid that reduces heartburn and s

  

• Zejula (niraparib) for the Treatment of Ovarian Cancer

  Zejula™ (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.

  

• Zelboraf (vemurafenib) Tablets – Treatment for Metastatic Melanoma

  Zelboraf is indicated for the treatment of metastatic melanoma and Erdheim-Chester disease.

  

• Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection

  Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.

  

• ZEPOSIA (Ozanimod) for the Treatment of Multiple Sclerosis

  ZEPOSIA® (Ozanimod) is the only FDA approved sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.

  

• Zepzelca (lurbinectedin) for the Treatment of Small Cell Lung Cancer

  Zepzelca™ (lurbinectedin) is a prescription medicine indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

  

• Zerbaxa (ceftolozane/tazobactam) for the Treatment of Gram-negative Bacterial Infections

  Zerbaxa (ceftolozane/tazobactam) is an antibiotic developed and marketed by Merck (formerly Cubist Pharmaceuticals (Cubist)), for the treatment of infections caused by gram-negative bacteria.

  

• Zilretta (triamcinolone acetonide extended-release injectable suspension) for the Treatment of Osteoarthritis Knee Pain

  Zilretta™ (triamcinolone acetonide extended-release injectable suspension) is a US Food and Drug Administration (FDA) approved extended-release intra-articular therapy indicated for the treatment of osteoarthritis knee pain.

  

• Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

  Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

  

• Zinforo (ceftaroline fosamil) for the Treatment of Complicated Skin and Soft Tissue Infections

  Zinforo (ceftaroline fosamil) is a new intravenous cephalosporin antibiotic indicated for the treatment of serious skin infections or community-acquired pneumonia.

  

• Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection

  Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment.

  

• Zioptan for the Reduction of Elevated Intraocular Pressure (IOP)

  Zioptan (tafluprost ophthalmic solution) was developed by Santen Pharmaceutical in collaboration with Merck. The drug is indicated for the reduction of elevated intraocular pressure (IOP). In February 2012, Zioptan received approval for the reduction of IOP in patients suffering from ocular hypertension or open-angle glaucoma.

  

• Zohydro (Hydrocodone Bitartrate) for the Treatment of Chronic Pain

  Zohydro (hydrocodone) is a single-entity oral drug indicated for the treatment of chronic pain. San Diego-based pharmaceutical company Zogenix developed and commercialised the drug in the US.

  

• Zokinvy (lonafarnib) for the Treatment of Progeria, USA

  Zokinvy (lonafarnib) is the first approved therapy for the group of ultra-rare genetic diseases collectively known as progeria.

  

• Zolgensma for the Treatment of Spinal Muscular Atrophy

  Zolgensma® (onasemnogene abeparvovec-xioi) is a one-time gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in paediatric patients.

  

• Zometa for Preventing Bone Cancer Complications

  Zometa is a bone resorption inhibitor indicated for the treatment of bone complications in patients with advanced cancer. It has several anticancer properties.

  

• Zonegran (Zonisamide) for the Treatment of Epilepsy

  Zonegran (Zonisamide) is an anti-epileptic drug indicated for the treatment of partial seizures in adults with epilepsy with or without secondary generalisation.

  

• Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events

  Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or peripheral arterial disease (PAD).

  

• Zorvolex (diclofenac) for the Treatment of AcutePain

  Zorvolex (diclofenac) is a nonsteroidal anti-inflammatory drug currently indicated for the treatment of mild to moderate acute pain in adults.

  

• ZTALMY (ganaxolone) for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder, USA

  ZTALMY® is the first FDA-approved therapy for seizures due to CDLK5 deficiency disorder in patients aged two years and older.
  

  

• Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence

  Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence.

  

• Zybrestat – Vascular Disrupting Agent and Cancer Therapy

  Zybrestat is a vascular disrupting agent (VDA) indicated for the treatment of anaplastic thyroid cancer and, potentially

  

• Zydelig (idelalisib) for the Treatment of Three B-cell Blood Cancers

  Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor and is used for the treatment of three B-cell blood cancers: relapsed chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL).

  

• Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

  Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC).

  

• Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia

  Zynteglo™ is a gene therapy indicated for the treatment of transfusion-dependent beta (β)-thalassemia (TDT) in patients aged 12 years and older.

  

• Zynyz for the Treatment of Merkel Cell Carcinoma, US

  The drug holds orphan drug designation by the FDA for the treatment of anal cancer.
  

  

• Zyprexa – Schizophrenia treatment

  Zyprexa (olanzapine) belongs to a newer group of antipsychotic medications called atypical antipsychotics and is widely

  

• Zytiga (abiraterone acetate) – Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research.